

Supplementary materials

Genetic architecture of lumbar spinal stenosis

Ville Salo^{1,2}, Juhani Määttä^{1,3}, Jasmin Takala^{2,3}, Anni Heikkilä^{2,3}, FinnGen⁵, Ene Reimann⁶, Reedik Mägi⁶, Estonian Biobank Research Team^{6,7}, Kadri Reis⁶, Abdelrahman G.Elhanas⁶, Anu Reigo⁶, Priit Palta^{6,8}, Tõnu Esko⁶, Ville Leinonen⁹, Jaro Karppinen^{1,3,10}, Eeva Sliz^{2,3*}, Johannes Kettunen^{2,3*}

¹ Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland

² Biocenter Oulu, Oulu, Finland

³ Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

⁴ Research unit of Population Health, Faculty of Medicine, and Biocenter Oulu, University of Oulu, Oulu, Finland

⁵ A list of FinnGen authors and their affiliations available in the supplements

⁶ Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

⁷ A list of Estonian Biobank Research Team authors and their affiliations available in the supplements

⁸ Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki

⁹ Neurosurgery, Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland and Department of Neurosurgery, Kuopio University Hospital, Kuopio, Finland

¹⁰ Rehabilitation Services of Wellbeing Services County of South Karelia, Lappeenranta, Finland

* These authors contributed equally to this work

Supplementary Note. FinnGen DF9 Ethics statement

Fig. S1 Lead variant effect estimates in every dataset

Fig. S2 Lead variant effect estimates in meta-analysis and sensitivity analysis

Fig. S3 MAGMA tissue expression analysis results

Fig. S4 Kaplan Meier plots for potential early-onset variants

Fig. S5.1 Scatterplot for whole body fat-free mass that could potentially be causal for LSS

Fig. S5.2 Scatterplot for body mass index (BMI) that could potentially be causal for LSS

Fig. S5.3 Scatterplot for hip circumference that could potentially be causal for LSS

Fig. S5.4 Scatterplot for whole body fat mass that could potentially be causal for LSS

Fig. S6 Scatterplot for back pain for which LSS is potentially causal

Fig. S7.1 Leave-one-out: Whole body fat-free mass -> LSS

Fig. S7.2 Leave-one-out: Body mass index (BMI) -> LSS

Fig. S7.3 Leave-one-out: Hip circumference -> LSS

Fig. S7.4 Leave-one-out: Whole body fat mass -> LSS

Fig. S8 Leave-one-out: LSS -> Back pain

Table S1 Study populations and phenotype characterization

Table S2 The lead variants at the 56 LSS-associated loci observed in the meta-analysis

Table S3 Structural information about lead variants and potential candidate genes

Table S4 Cohort level odds ratios and effect allele frequencies

Table S5 Effect estimate differences between meta-analysis and surgical GWAS

Table S6 FastBAT results

Table S7 eQTL colocalization results

Table S8 Cumulative morbidities and age differences between lead variant homozygotes

Table S9 Genetic correlations between LSS and 517 other traits

Table S10 Mendelian randomization results

Table S11 Bi-directional Mendelian randomization risk factors

References

Supplementary Note. FinnGen R9 Ethics statement

Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/202, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 9 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), AB20-5926 and amendment #1 (April 23 2020) and it's modification (Sep 22 2021), Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020.




Fig. S1. The forest plot displays the effect estimates and 95% confidence intervals for LSS-associated lead variants in the meta-analysis [green], as well as each dataset separately (FinnGen [orange], Estonian Biobank [red], and UK Biobank [blue]). Candidate gene, rsid and effect allele were used as variant identifiers. Table S4 displays the cohort level odds ratios and effect allele frequencies.




Fig. S2. A comparison of the effect sizes of the lead variants discovered in the original meta-analysis (Meta-analysis, ICD-10:M48.0 [green]) and in sensitivity analysis with LSS patients requiring surgery (Surgical GWAS, *Nomesco v1.15*: ABC36, ABC56, ABC66, ABC99, NAG61, NAG62, NAG63, NAG66, NAG67, and NAG99 [red]). Between meta-analysis and surgical GWAS we observed statistically significant effect differences for *NGF*, *RAB28*, *BMP6*, *TRIM38*, *AGMO*, *TNFSF11* and *ALDH1A2* variants (Fig. 1B). Results of the effect differences and p-values for difference can also be seen from Table S5.




Fig S3. MAGMA tissue expression analysis¹ results, no genome-wide significant results were observed in tissue expression analysis. y-axis, $-\log_{10}$ P-value; x-axis, tissues (GTEx Output-General tissues). Analysis was performed by using FUMA².




Fig. S4 Kaplan-Meier plots for variants located near the *OTUD7B*, *USP37*, *CDC5L*, *SOX5* and *SMAD3* genes. For these variants, we observed that the cumulative incidence of LSS differed between homozygotes already at the age of 40. The graphs on the left are based on FinnGen results, while those on the right are based on Estonian Biobank replication. Age in years is on the x-axis, and the corresponding fraction of the cases is on the y-axis. The grey line depicts homozygotes for the effect allele, the orange homozygotes for the other allele, and the blue line corresponds to heterozygotes having one copy of each allele. The heterozygote differences were not tested and are just shown for illustration.




Fig. S5.1 Scatterplot for whole body fat-free mass that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Whole body fat-free mass || id:ukb-b-13354” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of $r^2=0.001$ and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




Fig. S5.2 Scatterplot for body mass index (BMI) that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Body mass index (BMI) || id:ukb-b-19953” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of $r^2=0.001$ and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




Fig. S5.3 Scatterplot for hip circumference that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Hip circumference || id:ukb-b-15590” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of $r^2=0.001$ and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.




Fig. S5.4 Scatterplot for whole body fat mass that could potentially be causal for LSS. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Whole body fat mass || id:ukb-b-19393” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of $r^2=0.001$ and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.





Fig. S6 Scatterplot for back pain for which LSS is potentially causal. Genetic instruments for LSS were extracted from the meta-analysis conducted in FinnGen and Estonian Biobank. For “Pain type(s) experienced in last month: Back pain || id:ukb-b-9838” from the GWAS database provided by the MRC-IEU, which is integrated in the TwoSampleMR R library. European population references was utilised in LD pruning, with thresholds of $r^2=0.001$ and clumping window of 10kb. The error bars indicate the 95% confidence intervals of the SNP effects.



MR leave-one-out sensitivity analysis for
'Whole body fat-free mass II id:ukb-b-13354' on 'outcome'

Fig. S7.1 Leave-one-out: Whole body fat-free mass -> LSS




Fig. S7.2 Leave-one-out: Body mass index (BMI) -> LSS




Fig. S7.3 Leave-one-out: Hip circumference -> LSS




Fig. S7.4 Leave-one-out: Whole body fat mass -> LSS




Fig. S8.1 Leave-one-out: LSS -> Back pain

Table S1 Case and controls in all study populations and phenotype characterization.

Study population	Cases	Controls	Sample prevalence	Total
FinnGen	18 989	270 964	6.5%	289 953
Estonian Biobank	6146	66 533	8.4%	73 279
UK Biobank	5134	401 917	1.3%	407 051
Meta-analysis	30 269	739 414	3.9%	769 683
Sensitivity analysis (FinnGen)				
Surgical GWAS	8627	270 773	3.1%	279 400

Study	Revision / Codes	Codes
Meta-analysis		
EstBB	ICD-10	M48.0
UKBB	ICD-10	M48.0
FinnGen	ICD-10	M48.0
	ICD-9	7230A, 7240A, 7240B
FinnGen control exclusions	ICD-10	M40 (M40.0, M40.1, M40.2, M40.3, M40.4, M40.5), M41 (M41.0, M41.1, M41.2, M41.3, M41.4, M41.5, M41.6, M41.8, M41.9), M42 (M42.0, M42.1, M42.9), M43 (M43.0, M43.1, M43.2, M43.3, M43.4, M43.4, M43.5, M43.6, M43.8, M43.9), M45, M46 (M46.0, M46.1, M46.2, M46.3, M46.4, M46.5, M46.8, M46.9), M47 (M47.0, M47.1, M47.2, M47.8, M47.9), M48.1, M48.2, M48.3, M48.4, M48.5, M48.8, M48.9, M49 (M49.0, M49.1, M49.2, M49.3, M49.4, M49.5, M49.8), M50 (M50.0, M50.1, M50.2, M50.3, M50.8, M50.9), M51 (M51.1-M51.9), M53 (M53.0, M53.1, M53.2, M53.3, M53.8, M53.9), M54 (M54.0, M54.1, M54.2, M54.3, M54.4, M54.5, M54.6, M54.8, M54.9), M76 (M76.0, M76.1, M76.2, M76.3, M76.4, M76.5, M76.6, M76.7, M76.8, M76.9)
	ICD-9	737.0A, 727.1A, 737.2A, 738.4A, 723.5A, 732.8A, 732.8B, 732.8X, 732.9X, 737.9X, 720.0A, 720.2A, 720.8A, 720.9X, 721.0A, 721.1A, 721.2A, 721.3A, 721.4A, 724.0B, 721.6A, 722.7A, 722.7C, 722.4A, 722.0A, 722.7B, 722.4B, 722.8A, 723.2A, 723.3A, 724.6A, 724.8X, 724.9X, 724.4A, 723.4A, 723.1A, 724.2A, 724.1A, 724.5A, 726.5B, 726.6G, 726.6C, 726.6B, 726.6D, 726.7A, 726.6B, 726.6X, 726.7B, 726.7X, 722.1A, 722.1C, 722.3A, 722.5A, 722.5B, 722.6X, 722.8C, 722.9X
	ICD-8	71720, 73599, 73500, 71240, 71310, 71311, 71312, 71319, 72699, 71320, 72500, 72501, 72509, 72810, 72820, 72828, 78880, 78830, 78888, 72899, 72898, 72890, 72870, 71700, 72850, 72800, 72898, 72899, 72510, 72519, 72520, 72551, 72559, 72588, 72599
Sensitivity analysis (FinnGen)		
Surgical GWAS		
Step 1) Characterization of LSS patients		
	ICD-10	M48.0
	ICD-9	7230A, 7240A, 7240B
Step 2) Patients who have undergone surgery were selected from the characterized LSS patient group.		
	NOMESCO, version 1.15	ABC36, ABC56, ABC66, ABC99, NAG61, NAG62, NAG63, NAG66, NAG67, NAG99
Step 3) LSS cases that had not had surgery were omitted from the analysis. Patients who had undergone surgery but had not been diagnosed with LSS were also excluded. Otherwise, the control group was chosen in a similar manner as in the meta-analysis.		

Table S2. The lead variants at 54 LSS-associated ($p < 5 \times 10^{-8}$) loci in the meta-analysis. The meta-analysis consisted total of 30 269 cases and 739 414 controls from FinnGen, the Estonian Biobank, and the UK Biobank. Secondary signals were observed from four loci and conditional variants have been marked with *-symbol.

Locus	Candidate gene	CHR: POS	rsid	EA	OA	OR (95% CI)	p-value	EAF	Fin Enric.	Ref.
Meta-analysis (FinnGen, EstBB, UKBB)										
1p36.11	<i>RUNX3</i>	1:24894533	rs9438857	G	A	0.90 (0.88-0.92)	4.92e-08	0.31	0.86	Novel
1p13.2	<i>NGF</i>	1:115287365	rs6327	T	C	0.93 (0.91-0.95)	5.4e-16	0.47	1.06	Novel
"	<i>NGF*</i>	1:115170045	rs1286225	G	C	0.94 (0.92-0.96)	9.68e-11	0.68	1.01	
1q21.2	<i>OTUD7B</i>	1:149934520	rs11205303	C	T	0.92 (0.90-0.94)	1.76e-19	0.38	0.75	Novel
1q21.3	<i>ZNF687</i>	1:151032308	rs147042690	T	C	1.21 (1.14-1.27)	8.5e-09	0.01	34.27	Novel
1q32.1	<i>PTPRC</i>	1:198819354	rs72739729	C	G	0.91 (0.88-0.93)	2.18e-15	0.15	1.19	Novel
2p13.3	<i>GFPT1</i>	2:69341550	rs4340572	G	A	0.91 (0.89-0.93)	5.64e-25	0.57	0.95	3,4
"	<i>GFPT1*</i>	2:70422594	rs17500661	A	G	0.95 (0.93-0.97)	1.23e-08	0.29	1.06	
2q35	<i>USP37</i>	2:218486683	rs60362609	G	C	0.94 (0.92-0.96)	1.47e-08	0.61	0.98	Novel
3p21.31	<i>DAG1</i>	3:49498696	rs138073019	TTTA	T	0.95 (0.93-0.97)	9.31e-09	0.35	1.48	Novel
4p15.33	<i>RAB28</i>	4:12893286	rs3057070	A	AGAG	0.92 (0.90-0.94)	3.22e-15	0.24	1.08	Novel
5p13.1	<i>DAB2</i>	5:39844572	rs148346348	ATATG	A	1.08 (1.05-1.10)	7.56e-10	0.17	1.29	Novel
5q11.2	<i>ITGA2</i>	5:53038840	rs11747379	A	C	1.08 (1.05-1.10)	9.21e-11	0.18	1.07	Novel
5q33.3	<i>EBF1</i>	5:159017122	rs200608668	G	GC	1.06 (1.04-1.09)	3.28e-08	0.22	0.66	Novel
6p24.3	<i>BMP6</i>	6:7797607	rs10498672	G	C	1.08 (1.06-1.11)	9.09e-14	0.20	1.24	Novel
6p22.2	<i>TRIM38</i>	6:26239176	rs9358913	G	A	0.94 (0.93-0.96)	8.72e-10	0.32	1.62	Novel
6p22.1	<i>HLA</i>	6:30106665	rs62390186	A	T	0.94 (0.92-0.96)	3.99e-08	0.18	1.83	Novel
6p21.33	<i>HLA</i>	6:31133806	rs4294047	A	G	0.91 (0.88-0.93)	2.93e-13	0.11	1.97	Novel
6p21.32	<i>HLA</i>	6:32634706	rs17205170	T	G	0.92 (0.90-0.94)	3.33e-13	0.20	1.34	Novel
6p21.1	<i>CDC5L</i>	6:44479182	rs7770012	A	C	1.07 (1.05-1.08)	1.02e-12	0.53	0.99	Novel
6q21	<i>LIN28B</i>	6:105005542	rs314261	C	A	1.05 (1.03-1.07)	2.18e-08	0.57	1.03	Novel
6q22.1	<i>COL10A1</i>	6:116167743	rs7739896	G	A	0.95 (0.93-0.97)	4.57e-09	0.51	0.92	3
6q23.2	<i>EYA4</i>	6:132913577	rs2764217	A	G	1.06 (1.05-1.08)	1.36e-10	0.43	0.97	Novel
7p22.1	<i>FOKK1</i>	7:4638590	rs28658109	C	T	0.93 (0.91-0.96)	1.08e-08	0.19	1.35	Novel
7p21.2	<i>AGMO</i>	7:15344063	rs75674922	G	A	1.09 (1.06-1.11)	6.72e-12	0.13	1.83	3
7p21.1	<i>TWIST1</i>	7:19488615	rs2390116	T	C	0.95 (0.93-0.97)	2.93e-08	0.49	0.97	Novel
7p15.1	<i>JAZF1</i>	7:28156794	rs849135	A	G	0.95 (0.93-0.97)	7.32e-09	0.49	0.90	Novel
7q11.22	<i>Empty</i>	7:69064281	rs139203647	G	GT	1.08 (1.05-1.11)	1.01e-08	0.15	1.22	Novel
7q21.3	<i>DYNCL11</i>	7:95941237	rs11769842	C	T	1.08 (1.06-1.10)	1.18e-11	0.75	1.06	3
10p12.1	<i>MKX</i>	10:27612430	rs2637326	T	G	1.06 (1.05-1.08)	3.44e-12	0.47	0.73	Novel
11p14.1	<i>MPPED2</i>	11:30788512	rs607165	C	T	1.05 (1.04-1.07)	1.94e-09	0.44	1.19	Novel
12p12.2	<i>PDE3A</i>	12:20427791	rs73067286	A	T	0.93 (0.91-0.95)	2.1e-13	0.23	1.22	3
"	<i>PDE3A*</i>	12:20215335	rs60691990	C	T	0.93 (0.91-0.95)	1.86e-11	0.29	0.65	
12p12.1	<i>SOX5</i>	12:23821470	rs12308843	C	G	1.08 (1.06-1.10)	3.3e-15	0.27	1.28	Novel
12p11.22	<i>CCDC91</i>	12:27844985	rs7958415	T	C	0.93 (0.91-0.95)	1.07e-13	0.35	0.72	Novel
"	<i>CCDC91*</i>	12:27958482	rs189814310	C	A	0.65 (0.51-0.80)	3.20e-09	0.005	3.97	
"	<i>CCDC91*</i>	12:28156247	rs2127315	T	A	0.94 (0.92-0.96)	1.45e-08	0.25	0.85	
"	<i>CCDC91*</i>	12:28933226	rs11049924	A	C	0.93 (0.91-0.96)	2.90e-08	0.15	0.92	
12q14.1	<i>GLI1</i>	12:57749071	rs2069506	A	C	0.94 (0.93-0.96)	1.56e-09	0.33	1.19	Novel
12q14.1	<i>USP15</i>	12:62218131	rs11174377	A	G	1.07 (1.05-1.10)	2.47e-09	0.17	0.97	Novel
12q24.31	<i>ZCCHC8</i>	12:122480161	rs10846978	C	T	1.06 (1.04-1.09)	4.49e-08	0.77	1.07	Novel
13q14.11	<i>TNFSF11</i>	13:42423131	rs9594751	T	C	0.95 (0.93-0.97)	3.09e-08	0.25	1.13	Novel
13q31.1	<i>SLITRK6</i>	13:85356178	rs9531779	G	C	0.94 (0.93-0.96)	9.15e-11	0.59	1.03	3
14q11.2	<i>MMP14</i>	14:22843385	rs1042704	A	G	0.93 (0.91-0.96)	4.02e-10	0.22	1.00	Novel
14q32.33	<i>GPR132</i>	14:105137078	rs1022431	A	C	0.91 (0.88-0.95)	3.76e-08	0.09	0.78	Novel
15q21.3	<i>ALDH1A2</i>	15:58050948	rs4646570	C	G	1.06 (1.05-1.08)	5.47e-12	0.49	1.07	Novel
15q22.31	<i>PP1B</i>	15:64138226	rs148027154	A	T	1.28 (1.20-1.37)	3.52e-08	0.006	5.12	Novel
15q22.33	<i>SMAD3</i>	15:67072653	rs4776880	A	G	0.90 (0.88-0.92)	1.05e-28	0.35	1.10	3
15q25.3	<i>PDE8A</i>	15:84986797	rs11629962	T	C	0.94 (0.92-0.96)	2.36e-08	0.25	1.14	Novel
16q23.2	<i>GAN</i>	16:81482778	rs2966084	G	A	0.94 (0.92-0.96)	4.3e-11	0.69	0.95	Novel
17q12	<i>SOCS7</i>	17:38474030	rs113353816	C	T	1.06 (1.04-1.09)	4.25e-08	0.83	0.90	Novel
17q24.1	<i>AXIN2</i>	17:65278900	rs16961974	C	T	1.06 (1.04-1.07)	2.75e-08	0.28	1.05	Novel
17q24.3	<i>Empty</i>	17:71476022	rs12941198	C	A	1.06 (1.04-1.08)	3.6e-08	0.78	1.02	Novel
18q21.2	<i>DCC</i>	18:53220821	rs6508210	C	A	1.08 (1.06-1.09)	2.64e-16	0.52	0.85	Novel
19p13.3	<i>CACTIN</i>	19:3537186	rs77733715	G	A	1.14 (1.09-1.18)	1.44e-08	0.03	5.24	Novel
19p13.11	<i>CRLF1</i>	19:18616479	rs2074177	G	A	0.93 (0.91-0.95)	1.03e-12	0.25	1.05	Novel
20p13	<i>DDRGK1</i>	20:2800795	rs11697820	T	C	0.95 (0.93-0.96)	5.15e-10	0.58	0.98	Novel
21q22.2	<i>ETS2</i>	21:39183865	rs111901809	T	TAGA GGGG CAGG GGGC G	1.05 (1.03-1.07)	3.94e-08	0.49	1.32	Novel
22q12.2	<i>OSM</i>	22:30026719	rs2285645	T	C	0.83 (0.78-0.89)	4.19e-12	0.02	14.95	Novel
Xq23	<i>CHRDLI</i>	X:110450046	rs67648651	C	T	1.05 (1.04-1.07)	1.13e-11	0.40	0.87	Novel

Candidate gene, a gene at a new locus the biological function of which is likely to explain the LSS association; CHR: POS, chromosome and position (genome build hg38); rsid; SNP markers identification number; EA, effect allele; OA, other allele; OR, odds ratio; 95% CI, odds ratio 95% confidence interval; EAF, effect allele frequency; Fin Enric., enrichment in Finns (calculated FIN AF/NFEE AF in the Genome Aggregation Database [gnomAD, v.3.1.2], FIN AF is the allele frequency in Finns and NFEE AF is the allele frequency in Europeans (does not include Finns or Estonians)); REF, reference to literature reporting LSS association in the vicinity (± 1 MB) of the lead variant. *, for this variant p-value and OR have been adjusted for the effect of original lead variant at the locus through conditional analysis, the original lead variant is always above the conditional variant in the table

Table S3 Structural information about the LSS-associated and Surgical LSS variants. Also, biological functions for novel potential candidate genes that we determined with the help of literature and databases (Genbank⁵, UniProt⁶, GTEX-Portal⁷). HLA region variants were excluded from the PheWAS.

Candidate gene	rsid	Variant type	PheWAS ↑	PheWAS ↓	A possible function related to LSS pathogenesis
Meta-analysis (FinnGen, Estonian Biobank, UK Biobank)					
<i>RUNX3</i>	rs9438857	Downstream gene variant	-	-	<i>RUNX3</i> lowers CD8+ T cell counts, so it has a role in the regulation of immune defence ⁸ .
<i>NGF</i>	rs6327	Intron	Adhesive capsulitis	Carpal tunnel syndrome, arthrosis, spondylosis, spondylolisthesis, hallux valgus	<i>NGF</i> stimulates axonal regeneration in the central nervous system as well as collateral sprouting of the peripheral sensory nerves. <i>NGF</i> production can lead to nociceptive nerve ingrowth in the spine, and it is also involved in neuronal apoptosis ^{9,10} .
<i>OTUD7B</i>	rs11205303	Missense	Angina pectoris, cardiac arrhythmias, major coronary heart disease event, coronary atherosclerosis, coronary revascularization	Hallux valgus, lumbar disc herniation, carpal tunnel syndrome	<i>OTUD7B</i> controls non-canonical NF-κB activation through deubiquitination ¹¹ , its involvement in LSS pathogenesis has already been speculated in previous clinical studies concerning LSS ¹² .
<i>ZNF687</i>	rs147042690	Intron	-	-	<i>ZNF687</i> has been linked to Paget disease in earlier studies ^{13,14} . There is evidence that <i>ZNF687</i> may influence bone development and differentiation ¹⁵ .
<i>PTPRC</i>	rs72739729	Intron	-	Low back pain, Spondylosis, lumbar disc herniation	Regulates T cell antigen receptor signaling ^{16,17} .
<i>GFPT1</i>	rs4340572	Intron	Dupuytren contracture	Lumbar disc herniation, spondylosis, spondylolisthesis, cervical disc disorders	-
<i>USP37</i>	rs60362609	Intron	-	-	The hedgehog pathway, which is regulated by <i>USP37</i> , has previously been connected to ligamentum flavum hypertrophy along with <i>GLII</i> ¹⁸⁻²⁰ .
<i>DAG1</i>	rs138073019	Intron	Ulcerative proctitis, inflammatory bowel disease, ulcerative colitis	Pain, spondylosis, shoulder lesions, lumbar disc herniation, hypertension, carpal tunnel syndrome	<i>DAG1</i> plays a role in neural development and has a known role in axon guidance ^{21,22} . It has also been linked to muscle dystrophies ²³ .
<i>RAB28</i>	rs5856174	Intergenic	-	-	<i>RAB28</i> has been linked to kyphosis (curvature of the spine) in a previous study ²⁴ , the genetic mechanism of action is potentially related to membrane trafficking or regulation of NF-κB nuclear transportation ^{25,26} .
<i>DAB2</i>	rs148346348	Intergenic	Spondylolisthesis	-	<i>DAB2</i> has multifaceted roles in signaling pathways involved in cellular differentiation, proliferation, migration, and it may contribute to immunological tolerance and suppression of inflammatory responses.

					In addition, it has been linked to TGF- β signaling ^{27,28} .
<i>ITGA2</i>	rs11747379	Intron	Lumbar disc herniation, spondylolisthesis		A transmembrane receptor for collagens and other related proteins, the alpha subunit is encoded by <i>ITGA2</i> , also referred to as integrin $\alpha 2$. <i>ITGA2</i> mediates the adhesion of various cell types to the extracellular matrix (ECM) by forming a heterodimer with an integrin beta subunit ²⁹ .
<i>EBF1</i>	rs200608668	Intron	Obesity, hypertension	Varicose veins	<i>EBF1</i> regulates early B-cell differentiation by poising or activating lineage-specific genes and repressing genes associated with alternative cell fates ^{30,31} .
<i>BMP6</i>	rs10498672	Intron	Arthrosis, coxarthrosis		<i>BMP6</i> has an important role in bone and cartilage formation and repair ^{32,33} . It also potentially plays a role in inducing angiogenesis and neurogenesis ^{34,35} .
<i>TRIM38</i>	rs9358913	Upstream gene variant	Subacute thyroiditis	Hypothyroidism, atherosclerosis, hypertension, varicose veins, coeliac disease, arthrosis, gonarthrosis, autoimmune disease	<i>TRIM38</i> is an inflammatory modulator ³⁶ . By suppressing NF- κ B signalling, <i>TRIM38</i> can lessen apoptosis and degeneration of chondrocytes caused by IL-1 β , it has been suggested that <i>TRIM38</i> may be involved in osteoarthritis ³⁷ .
<i>HLA</i>	rs62390186	Intron	-	-	-
<i>HLA</i>	rs4294047	Intron	-	-	-
<i>HLA</i>	rs17205170	Intron	-	-	-
<i>CDC5L</i>	rs7770012	Intergenic	Bell's palsy, lumbar disc herniation, coxarthrosis, arthrosis	-	<i>CDC5L</i> has previously been associated with ossification of the posterior longitudinal ligament (OPLL) ^{38,39} . It has been discovered that <i>CDC5L</i> stimulates early chondrogenesis and cartilage growth and may contribute to the pathophysiology of OPLL by initiating the endochondral ossification process ⁴⁰ .
<i>LIN28B</i>	rs314261	Intron	Carpal tunnel syndrome, lumbar disc herniation, spondylosis		<i>LIN28B</i> has been associated with bone mineral density (BMD) ⁴¹ .
<i>COL10A1</i>	rs7739896	Intron	Myopia	Gonarthrosis, spondylolisthesis	-
<i>EYA4</i>	rs2764217	Intergenic	-	-	Through bone remodelling, <i>EYA4</i> has been found to have an effect on BMD ⁴² .
<i>FOKX1</i>	rs28658109	Intergenic	-	-	It has been discovered that <i>FOKX1</i> acts via the TGF- β pathway and has been associated with BMD ⁴³ . Degenerative diseases of the spine have also been linked to the TGF- β pathway ^{44,45} .
<i>AGMO</i>	rs75674922	Intron	-	-	-
<i>TWIST1</i>	rs2390116	Intron	-	Lumbar disc herniation	<i>TWIST1</i> has been found to be an inflammatory regulator ⁴⁶ , and has also been associated with lumbar disc herniation (LDH) ^{47,48} .

JAZF1	rs849135	Intron	Actinic keratosis, basal cell carcinoma	Type II diabetes, asthma, statin medication, coxarthrosis	<i>JAZF1</i> is a transcriptional repressor, which has been associated to height and spine length in addition to lowering IGF-1 serum concentrations ^{49,50} .
Empty	rs139203647	Intergenic	-	-	-
DYNC111	rs11769842	Intron	-	-	-
MKX	rs2637326	Intergenic	Low back pain, spondylosis, lumbar disc herniation	Nonsuppurative otitis media	In addition to its well-known function in the development of tendons and ligaments, <i>MKX</i> has been discovered to be a crucial transcription factor in the formation of the intervertebral disc's annulus fibrosus ^{51,52} . <i>MKX</i> has also previously been associated with LDH ^{47,48} .
MPPED2	rs607165	Intergenic	Hypertension, cervical disc disorders, arthrosis, spondylosis, depression medications	-	<i>MPPED2</i> regulates many cellular functions, such as differentiation, proliferation, and apoptosis, it also possibly regulates systemic inflammation ^{53,54} .
PDE3A	rs73067286	Intron	Umbilical hernia	Type II diabetes	-
SOX5	rs12308843	Intron	Arthrosis, lumbar disc herniation, spondylosis, gonarthrosis, low back pain		Transcription factor involved in chondrocytes differentiation and cartilage formation ⁵⁵⁻⁵⁷ .
CCDC91	rs7958415	Regulatory region variant	-	-	<i>CCDC91</i> has been previously associated with OPLL and may have a role in the regulation of osteogenesis ^{39,58} .
GLI1	rs2069506	3 prime UTR variant	-	Lumbar disc herniation	<i>GLI1</i> is an activator and is highly expressed in proliferating chondrocytes and the perichondrium adjacent to the prehypertrophic and hypertrophic zones ⁵⁹ . <i>GLI1</i> expression has been found to be increased in hypertrophic ligamentum flavum (LF) and is required for the fibrogenesis of fibroblasts. Hypertrophy of the LF is a significant contributor to LSS ¹⁹ .
USP15	rs11174377	Intron	-	-	<i>USP15</i> is an important regulator of TGF- β and BMP-signalling pathways; it modulates an alternative β -catenin pathway that stimulates bone formation, it is also a positive modulator of both TNF- α - and IL-1 β -stimulated NF- κ B activation ^{18,60} .
ZCCHC8	rs10846978	Intron	Spondylosis, obesity	-	<i>ZCCHC8</i> is part of the NEXT complex, which regulates mRNA splicing ⁶¹ . <i>ZCCHC8</i> has also been found to play a role in the development of the central nervous system ^{62,63} .
TNFSF11	rs9594751	Intron	-	-	Through bone remodelling, <i>TNFSF11</i> has been found to have an effect on BMD ⁴² .
SLITRK6	rs9531779	Intergenic	-	-	-
MMP14	rs1042704	Missense	Adhesive capsulitis, dupuytren	Lumbar disc herniation	<i>MMP14</i> missense variant is known to reduce collagen catabolism ⁶⁴ .

			contracture, shoulder lesions, fibroblastic disorders		and through that it can be related to spinal degeneration ⁶⁵ .
<i>GPR132</i>	rs1022431	Downstream gene variant	-	-	<i>GPR132</i> reduces inflammatory responses by decreasing the number of immune cells and the release of proinflammatory cytokines and growth factors at the site of nerve injury ⁶⁶ .
<i>ALDH1A2</i>	rs4646570	Intron	Coxarthrosis, polyarthrosis	-	The enzyme retinaldehyde dehydrogenase 2, which is encoded by <i>ALDH1A2</i> , catalyses the conversion of retinaldehyde to retinoic acid, which has a role in maintaining bone and cartilage tissues. <i>ALDH1A2</i> has also been associated with osteoarthritis ⁶⁷⁻⁶⁹ .
<i>PPIB</i>	rs148027154	3 prime UTR variant	-	-	<i>PPIB</i> is involved in procollagen export and secretion ⁷⁰ . Certain <i>PPIB</i> variants have been found to be associated with osteogenesis imperfecta ⁷¹ .
<i>SMAD3</i>	rs4776880	Intron	-	Sciatica, hallux valgus, lumbar disc herniation, spondylosis, cervical disc disorders, coxarthrosis, spondylolisthesis	-
<i>PDE8A</i>	rs11629962	Intron	-	-	<i>PDE8A</i> has a role in T-cell activation ⁷² , and through the cAMP pathway, it participates in the regulation of many biological pathways ⁷³ .
<i>GAN</i>	rs2966084	Intron	-	Hypertension, type II diabetes	Mutations in the <i>GAN</i> gene cause giant axonal neuropathy, a severe form of sensory and motor neuropathy. Axonal degeneration is accompanied by the accumulation and aggregation of cytoskeletal components. According to these findings, <i>GAN</i> plays a critical role in axonal structure and neuron maintenance ⁷⁴ .
<i>SOCS7</i>	rs113353816	Intron	-	-	<i>SOCS7</i> regulates a variety of signalling pathways ⁷⁵ .
<i>AXIN2</i>	rs16961974	Regulatory region variant	Osteoporosis	-	<i>AXIN2</i> is most likely engaged in controlling β -catenin within the Wnt-signaling pathway ⁷⁶ . The Wnt-signaling pathway is linked to autoimmunity, bone and cartilage regeneration, and repair ⁷⁷ .
<i>Empty DCC</i>	rs12941198 rs6508210	Intergenic Intron	- Sciatica, obesity, metabolic disorders, depression, any mental disorder, pain, low back pain, spondylosis, depression medications, lumbar disc herniation	- -	- <i>DCC</i> might have a role in neurovascular ingrowth/axonal guidance ^{78,79} .

<i>CACTIN</i>	rs77733715	3 prime UTR variant	Malignant melanoma of skin	-	-	<i>CACTIN</i> has been associated with longitudinal pediatric bone accrual, it has been annotated to the toll-like receptor pathway which has a role in osteoblast function, including mediating bone inflammatory responses and regulating cell viability, proliferation, and osteoblast-mediated osteoclastogenesis ⁸⁰ .
<i>CRLF1</i>	rs2074177	Intron	-	-	-	One frequent cause of LSS is ligamentum flavum hypertrophy ¹⁹ . Through the ERK signalling pathway, <i>CRLF1</i> increases LF fibrosis and plays a part in mediating the effects of TGF-β1 ⁸¹ .
<i>DDRGI1</i>	rs11697820	Upstream gene variant	-	-	-	Potentially acting as an NF-κB regulator ⁸² , <i>DDRGI1</i> can also bind directly to <i>SOX9</i> , preventing its ubiquitination and proteasomal degradation, which can affect the chondrogenesis ⁸³ .
<i>ETS2</i>	rs111901809	Upstream gene variant	-	Atrial fibrillation and flutter, cardiac arrhythmias	-	Through osteoblast differentiation and bone formation, <i>ETS2</i> potentially plays a role in skeletal development ⁸⁴ .
<i>OSM</i>	rs2285645	3 prime UTR variant	-	-	-	<i>OSM</i> is a growth and cytokine production regulator that has been found to have the ability to stimulate bone accrual ^{85,86} .
<i>CHRD1</i>	rs67648651	Intron	Carpal tunnel syndrome, lumbar disc herniation	Coronary revascularization, hernia, hypercholesterolemia, statin medication, metabolic disorders,	-	Through its potential to affect the activity of the BMP- and SMAD-signalling pathways, <i>CHRD1</i> may play a significant role in osteogenic differentiation, bone remodelling and neuronal differentiation ^{87,88} .
<i>Surgical GWAS (FinnGen)</i>						
<i>FOXO1</i>	rs12872985	Intron	Leiomyoma of uterus, lumbar disc herniation	-	-	In addition to being required for <i>SOX9</i> expression, <i>FOXO1</i> also plays a crucial role in cell-cycle arrest during chondrogenic differentiation through TGFβ1 signalling ⁸⁹ . It also plays a role in B-cell differentiation ⁹⁰ .

Candidate gene, a gene at a novel locus which biological function is likely to explain the LSS or LSS surgical GWAS association; rsid, SNP markers identification number, Variant type, genomic location of associated variant, PheWAS results for the LSS-associated variants, with an arrow showing the direction of the association. Only associations that reached genome-wide significance ($p < 5 \times 10^{-8}$) are reported.

Table S4. The lead variants at 54 LSS-associated ($p < 5 \times 10^{-8}$) loci in the meta-analysis of 30 269 LSS cases and 739 414 controls from FinnGen, the Estonian Biobank, and the UK Biobank. Odds ratios and their 95% confidence intervals for each LSS-associated variant both in the meta-analysis and in each dataset separately. EAF, effect allele frequency.

Candidate gene	CHR:POS	EA	OA	Cohort	OR (95 % CI)	EAF
<i>RUNX3</i>	1:24894533	G	A	Meta-analysis	0.90 (0.88-0.92)	0.31
				FinnGen	0.94 (0.91-0.96)	0.30
				UK Biobank	1.01 (0.97-1.05)	0.32
				Estonian Biobank	0.92 (0.87-0.97)	0.32
<i>NGF</i>	1:115287365	T	C	Meta-analysis	0.93 (0.91-0.95)	0.47
				FinnGen	0.93 (0.91-0.96)	0.47
				UK Biobank	0.92 (0.88-0.96)	0.46
				Estonian Biobank	0.96 (0.92-1.01)	0.47
<i>OTUD7B</i>	1:149934520	C	T	Meta-analysis	0.92 (0.90-0.94)	0.38
				FinnGen	0.91 (0.89-0.94)	0.33
				UK Biobank	0.92 (0.88-0.96)	0.41
				Estonian Biobank	0.93 (0.89-0.98)	0.36
<i>ZNF687</i>	1:151032308	T	C	Meta-analysis	1.21 (1.14-1.27)	0.01
				FinnGen	1.20 (1.13-1.26)	0.03
				UK Biobank	1.71 (0.22-3.21)	0.0002
				Estonian Biobank	1.34 (1.05-1.62)	0.006
<i>PTPRC</i>	1:198819354	C	G	Meta-analysis	0.91 (0.88-0.93)	0.15
				FinnGen	0.90 (0.87-0.93)	0.16
				UK Biobank	0.93 (0.87-0.99)	0.13
				Estonian Biobank	0.90 (0.85-0.96)	0.20
<i>GFPT1</i>	2:69341550	G	A	Meta-analysis	0.91 (0.89-0.93)	0.57
				FinnGen	0.92 (0.89-0.94)	0.55
				UK Biobank	0.91 (0.87-0.95)	0.58
				Estonian Biobank	0.90 (0.86-0.95)	0.58
<i>USP37</i>	2:218486683	G	C	Meta-analysis	0.94 (0.92-0.96)	0.61
				FinnGen	0.94 (0.92-0.96)	0.61
				UK Biobank	-	-
				Estonian Biobank	0.95 (0.91-1.00)	0.62
<i>DAG1</i>	3:49498696	TTTA	T	Meta-analysis	0.95 (0.93-0.97)	0.35
				FinnGen	0.95 (0.92-0.97)	0.44
				UK Biobank	0.95 (0.91-1.00)	0.32
				Estonian Biobank	0.96 (0.91-1.01)	0.30
<i>RAB28</i>	4:12893286	A	AGAG	Meta-analysis	0.92 (0.90-0.94)	0.24
				FinnGen	0.92 (0.89-0.94)	0.25
				UK Biobank	0.91 (0.86-0.95)	0.24
				Estonian Biobank	0.95 (0.90-1.00)	0.23
<i>DAB2</i>	5:39844572	ATATG	A	Meta-analysis	1.08 (1.05-1.10)	0.17
				FinnGen	1.09 (1.06-1.11)	0.19
				UK Biobank	1.05 (0.99-1.10)	0.16
				Estonian Biobank	-	-
<i>ITGA2</i>	5:53038840	A	C	Meta-analysis	1.08 (1.05-1.10)	0.18
				FinnGen	1.07 (1.04-1.10)	0.19
				UK Biobank	1.10 (1.05-1.15)	0.18
				Estonian Biobank	1.08 (1.02-1.14)	0.16
<i>EBF1</i>	5:159017122	G	GC	Meta-analysis	1.06 (1.04-1.09)	0.22
				FinnGen	1.06 (1.03-1.09)	0.17
				UK Biobank	1.07 (1.02-1.12)	0.24
				Estonian Biobank	1.06 (1.01-1.11)	0.27
<i>BMP6</i>	6:7797607	G	C	Meta-analysis	1.08 (1.06-1.11)	0.20
				FinnGen	1.09 (1.06-1.11)	0.22
				UK Biobank	1.09 (1.04-1.14)	0.18
				Estonian Biobank	1.07 (1.01-1.12)	0.19
<i>TRIM38</i>	6:26239176	G	A	Meta-analysis	0.94 (0.93-0.96)	0.32
				FinnGen	0.94 (0.92-0.96)	0.41
				UK Biobank	0.94 (0.89-0.98)	0.26
				Estonian Biobank	0.97 (0.93-1.02)	0.34
<i>HLA</i>	6:30106665	A	T	Meta-analysis	0.94 (0.92-0.96)	0.18
				FinnGen	0.93 (0.90-0.95)	0.23
				UK Biobank	0.95 (0.89-1.01)	0.14
				Estonian Biobank	1.00 (0.94-1.06)	0.16
<i>HLA</i>	6:31133806	A	G	Meta-analysis	0.91 (0.88-0.93)	0.11
				FinnGen	0.89 (0.86-0.92)	0.16
				UK Biobank	0.95 (0.87-1.02)	0.07
				Estonian Biobank	0.95 (0.87-1.02)	0.10
<i>HLA</i>	6:32634706	T	G	Meta-analysis	0.92 (0.90-0.94)	0.20
				FinnGen	0.92 (0.89-0.94)	0.24
				UK Biobank	0.93 (0.88-0.98)	0.18
				Estonian Biobank	-	-
<i>CDC5L</i>	6:44479182	A	C	Meta-analysis	1.07 (1.05-1.08)	0.53
				FinnGen	1.06 (1.04-1.08)	0.53
				UK Biobank	1.10 (1.06-1.14)	0.53
				Estonian Biobank	1.05 (1.01-1.10)	0.53
<i>LIN28B</i>	6:105005542	C	A	Meta-analysis	1.05 (1.03-1.07)	0.57
				FinnGen	1.05 (1.03-1.07)	0.59
				UK Biobank	1.07 (1.03-1.11)	0.56
				Estonian Biobank	1.03 (0.99-1.08)	0.55

<i>COL10A1</i>	6:116167743	G	A	Meta-analysis	0.95 (0.93-0.97)	0.51
				FinnGen	0.95 (0.92-0.97)	0.50
				UK Biobank	0.94 (0.90-0.98)	0.53
				Estonian Biobank	0.98 (0.93-1.02)	0.47
<i>EYA4</i>	6:132913577	A	G	Meta-analysis	1.06 (1.05-1.08)	0.43
				FinnGen	1.07 (1.04-1.09)	0.41
				UK Biobank	1.06 (1.02-1.10)	0.44
				Estonian Biobank	-	-
<i>FOXK1</i>	7:4638590	C	T	Meta-analysis	0.93 (0.91-0.96)	0.19
				FinnGen	0.94 (0.91-0.96)	0.23
				UK Biobank	0.92 (0.86-0.97)	0.17
				Estonian Biobank	-	-
<i>AGMO</i>	7:15344063	G	A	Meta-analysis	1.09 (1.06-1.11)	0.13
				FinnGen	1.11 (1.08-1.13)	0.17
				UK Biobank	1.06 (1.00-1.13)	0.11
				Estonian Biobank	1.01 (0.94-1.08)	0.11
<i>TWIST1</i>	7:19488615	T	C	Meta-analysis	0.95 (0.93-0.97)	0.49
				FinnGen	0.95 (0.93-0.97)	0.48
				UK Biobank	0.93 (0.89-0.97)	0.50
				Estonian Biobank	0.97 (0.93-1.02)	0.49
<i>JAZF1</i>	7:28156794	A	G	Meta-analysis	0.95 (0.93-0.97)	0.49
				FinnGen	0.96 (0.94-0.98)	0.47
				UK Biobank	0.94 (0.90-0.98)	0.50
				Estonian Biobank	0.93 (0.89-0.98)	0.50
<i>Empty</i>	7:69064281	G	GT	Meta-analysis	1.08 (1.05-1.11)	0.15
				FinnGen	1.08 (1.05-1.11)	0.16
				UK Biobank	1.09 (1.03-1.15)	0.14
				Estonian Biobank	-	-
<i>DYNC111</i>	7:95941237	C	T	Meta-analysis	1.08 (1.06-1.10)	0.75
				FinnGen	1.08 (1.05-1.10)	0.77
				UK Biobank	1.10 (1.06-1.15)	0.74
				Estonian Biobank	-	-
<i>MKX</i>	10:27612430	T	G	Meta-analysis	1.06 (1.05-1.08)	0.47
				FinnGen	1.05 (1.03-1.08)	0.40
				UK Biobank	1.06 (1.02-1.10)	0.51
				Estonian Biobank	1.11 (1.07-1.16)	0.49
<i>MPPED2</i>	11:30788512	C	T	Meta-analysis	1.05 (1.04-1.07)	0.44
				FinnGen	1.06 (1.04-1.08)	0.48
				UK Biobank	1.04 (1.00-1.08)	0.42
				Estonian Biobank	1.06 (1.10-1.10)	0.43
<i>PDE3A</i>	12:20427791	A	T	Meta-analysis	0.93 (0.91-0.95)	0.23
				FinnGen	0.93 (0.90-0.95)	0.26
				UK Biobank	0.91 (0.86-0.95)	0.21
				Estonian Biobank	0.94 (0.90-0.99)	0.31
<i>SOX5</i>	12:23821470	C	G	Meta-analysis	1.08 (1.06-1.10)	0.27
				FinnGen	1.07 (1.05-1.10)	0.31
				UK Biobank	1.08 (1.03-1.12)	0.23
				Estonian Biobank	1.10 (1.05-1.15)	0.32
<i>CCDC91</i>	12:27844985	T	C	Meta-analysis	0.93 (0.91-0.95)	0.35
				FinnGen	0.93 (0.91-0.95)	0.31
				UK Biobank	0.94 (0.90-0.98)	0.38
				Estonian Biobank	0.93 (0.89-0.98)	0.39
<i>GLI1</i>	12:57749071	A	C	Meta-analysis	0.94 (0.93-0.96)	0.33
				FinnGen	0.92 (0.88-0.95)	0.34
				UK Biobank	0.97 (0.91-1.02)	0.32
				Estonian Biobank	0.94 (0.88-1.01)	0.36
<i>USP15</i>	12:62218131	A	G	Meta-analysis	1.07 (1.05-1.10)	0.17
				FinnGen	1.07 (1.04-1.10)	0.17
				UK Biobank	1.10 (1.04-1.15)	0.16
				Estonian Biobank	1.07 (1.01-1.13)	0.18
<i>ZCCHC8</i>	12:122480161	C	T	Meta-analysis	1.06 (1.04-1.09)	0.77
				FinnGen	1.05 (1.02-1.08)	0.80
				UK Biobank	1.09 (1.04-1.13)	0.74
				Estonian Biobank	1.06 (1.01-1.12)	0.76
<i>TNFSF11</i>	13:42423131	T	C	Meta-analysis	0.95 (0.93-0.97)	0.25
				FinnGen	0.94 (0.92-0.96)	0.27
				UK Biobank	0.93 (0.88-0.97)	0.23
				Estonian Biobank	0.99 (0.94-1.04)	0.27
<i>SLITRK6</i>	13:85356178	G	C	Meta-analysis	0.94 (0.93-0.96)	0.59
				FinnGen	0.94 (0.92-0.96)	0.59
				UK Biobank	0.93 (0.89-0.97)	0.60
				Estonian Biobank	0.97 (0.93-1.02)	0.54
<i>MMP14</i>	14:22843385	A	G	Meta-analysis	0.93 (0.91-0.96)	0.21
				FinnGen	0.93 (0.90-0.96)	0.21
				UK Biobank	0.94 (0.89-0.99)	0.21
				Estonian Biobank	0.95 (0.90-1.00)	0.21
<i>GPR132</i>	14:105137078	A	C	Meta-analysis	0.91 (0.88-0.95)	0.09
				FinnGen	0.90 (0.86-0.94)	0.07
				UK Biobank	0.93 (0.87-1.00)	0.11
				Estonian Biobank	0.92 (0.84-1.01)	0.09
<i>ALDH1A2</i>	15:58050948	C	G	Meta-analysis	1.06 (1.05-1.08)	0.49

				FinnGen	1.07 (1.04-1.09)	0.49
				UK Biobank	1.06 (1.02-1.10)	0.49
				Estonian Biobank	1.05 (1.01-1.10)	0.47
<i>PPIB</i>	15:64138226	A	T	Meta-analysis	1.28 (1.20-1.37)	0.006
				FinnGen	1.27 (1.18-1.36)	0.01
				UK Biobank	2.12 (1.02-1.10)	0.002
				Estonian Biobank	1.22 (0.80-1.64)	0.003
<i>SMAD3</i>	15:67072653	A	G	Meta-analysis	0.90 (0.88-0.92)	0.35
				FinnGen	0.91 (0.89-0.93)	0.37
				UK Biobank	0.88 (0.84-0.92)	0.33
				Estonian Biobank	0.89 (0.85-0.94)	0.41
<i>PDE8A</i>	15:84986797	T	C	Meta-analysis	0.94 (0.92-0.96)	0.25
				FinnGen	0.93 (0.91-0.96)	0.27
				UK Biobank	0.96 (0.92-1.01)	0.24
				Estonian Biobank	-	-
<i>GAN</i>	16:81482778	G	A	Meta-analysis	0.94 (0.92-0.96)	0.69
				FinnGen	0.94 (0.92-0.96)	0.67
				UK Biobank	0.93 (0.88-0.97)	0.71
				Estonian Biobank	0.95 (0.90-1.00)	0.72
<i>SOCS7</i>	17:38474030	C	T	Meta-analysis	1.06 (1.04-1.09)	0.83
				FinnGen	1.08 (1.05-1.10)	0.79
				UK Biobank	1.02 (0.97-1.08)	0.86
				Estonian Biobank	1.06 (1.00-1.12)	0.81
<i>AXIN2</i>	17:65278900	C	T	Meta-analysis	1.06 (1.04-1.07)	0.28
				FinnGen	1.06 (1.03-1.08)	0.29
				UK Biobank	1.03 (0.98-1.08)	0.26
				Estonian Biobank	1.07 (1.03-1.12)	0.36
<i>Empty</i>	17:71476022	C	A	Meta-analysis	1.06 (1.04-1.08)	0.78
				FinnGen	1.06 (1.03-1.09)	0.78
				UK Biobank	1.09 (1.05-1.14)	0.78
				Estonian Biobank	1.03 (0.98-1.08)	0.78
<i>DCC</i>	18:53220821	C	A	Meta-analysis	1.08 (1.06-1.09)	0.52
				FinnGen	1.08 (1.06-1.10)	0.49
				UK Biobank	1.07 (1.03-1.11)	0.53
				Estonian Biobank	1.05 (1.01-1.10)	0.56
<i>CACTIN</i>	19:3537186	G	A	Meta-analysis	1.14 (1.09-1.18)	0.03
				FinnGen	1.15 (1.10-1.19)	0.05
				UK Biobank	1.22 (1.00-1.43)	0.009
				Estonian Biobank	1.06 (0.92-1.19)	0.03
<i>CRLF1</i>	19:18616479	G	A	Meta-analysis	0.93 (0.91-0.95)	0.25
				FinnGen	0.93 (0.90-0.95)	0.25
				UK Biobank	0.91 (0.86-0.96)	0.24
				Estonian Biobank	0.96 (0.90-1.01)	0.26
<i>DDRGI1</i>	20:2800795	T	C	Meta-analysis	0.95 (0.93-0.96)	0.58
				FinnGen	0.95 (0.93-0.97)	0.58
				UK Biobank	0.92 (0.88-0.96)	0.59
				Estonian Biobank	0.96 (0.91-1.00)	0.56
<i>ETS2</i>	21:39183865	T	TAGAGGGCA GGGGGCG	Meta-analysis	1.05 (1.03-1.07)	0.49
				FinnGen	1.04 (1.02-1.07)	0.56
				UK Biobank	1.09 (1.05-1.13)	0.44
				Estonian Biobank	1.04 (0.99-1.08)	0.53
<i>OSM</i>	22:30026719	T	C	Meta-analysis	0.83 (0.78-0.89)	0.02
				FinnGen	0.83 (0.78-0.89)	0.05
				UK Biobank	0.76 (0.15-1.37)	0.001
				Estonian Biobank	0.84 (0.68-1.01)	0.02
<i>CHRD1</i>	X:110450046	C	T	Meta-analysis	1.05 (1.04-1.07)	0.40
				FinnGen	1.05 (1.03-1.06)	0.38
				UK Biobank	1.07 (1.04-1.10)	0.41
				Estonian Biobank	1.06 (1.02-1.10)	0.39

Table S5. Meta-analysis and surgical GWAS effect differences for every LSS-associated variant. Two-tailed test was used for statistical testing, for that we used following formula: $((Effect_Meta - Effect_SURG)/\sqrt{standarderror_Meta^2 + standarderror_SURG^2})$, $P_diff = 2*(1-dif)$. $P_{diff} < 0.05$ was considered as a threshold for statistical significance.

Candidate gene	rsid	Effect Meta	Effect SURG	Standard error Meta	Standard error SURG	P_diff
<i>RUNX3</i>	rs9438857	-0,053	-0,086	0,010	0,017	0,101
<i>NGF</i>	rs6327	-0,072	-0,109	0,009	0,016	0,042
<i>OTUD7B</i>	rs11205303	-0,085	-0,118	0,009	0,017	0,100
<i>ZNF687</i>	rs147042690	0,188	0,211	0,033	0,047	0,691
<i>PTPRC</i>	rs72739729	-0,097	-0,121	0,012	0,022	0,337
<i>GFPT1</i>	rs4340572	-0,092	-0,109	0,009	0,016	0,337
<i>USP37</i>	rs60362609	-0,057	-0,063	0,010	0,016	0,771
<i>DAG1</i>	rs138073019	-0,053	-0,062	0,009	0,016	0,629
<i>RAB28</i>	rs5856174	-0,082	-0,125	0,010	0,019	0,043
<i>ITGA2</i>	rs148346348	0,076	0,095	0,012	0,020	0,431
<i>DAB2</i>	rs11747379	0,074	0,079	0,011	0,020	0,805
<i>EBF1</i>	rs200608668	0,062	0,070	0,011	0,021	0,707
<i>BMP6</i>	rs10498672	0,081	0,143	0,011	0,019	0,004
<i>TRIM38</i>	rs9358913	-0,057	-0,093	0,009	0,016	0,049
<i>HLA</i>	rs62390186	-0,062	-0,100	0,011	0,019	0,085
<i>HLA</i>	rs4294047	-0,097	-0,112	0,013	0,022	0,573
<i>HLA</i>	rs17205170	-0,085	-0,086	0,012	0,019	0,953
<i>CDC5L</i>	rs7770012	0,064	0,082	0,009	0,016	0,305
<i>LIN28B</i>	rs314261	0,050	0,061	0,009	0,016	0,576
<i>COL10A1</i>	rs7739896	-0,052	-0,082	0,009	0,016	0,095
<i>EYA4</i>	rs2764217	0,063	0,068	0,010	0,016	0,781
<i>FOKX1</i>	rs28658109	-0,068	-0,058	0,012	0,019	0,651
<i>AGMO</i>	rs75674922	0,085	0,135	0,012	0,020	0,038
<i>TWIST1</i>	rs2390116	-0,050	-0,066	0,009	0,016	0,364
<i>JAZF1</i>	rs849135	-0,052	-0,060	0,009	0,016	0,658
Empty	rs139203647	0,076	0,090	0,013	0,021	0,579
<i>DYNC111</i>	rs11769842	0,079	0,079	0,012	0,019	0,999
<i>MKX</i>	rs2637326	0,063	0,062	0,009	0,016	0,992
<i>MPPED2</i>	rs607165	0,053	0,048	0,009	0,016	0,748
<i>PDE3A</i>	rs73067286	-0,076	-0,086	0,010	0,018	0,609
<i>SOX5</i>	rs12308843	0,077	0,057	0,010	0,017	0,308
<i>CCDC91</i>	rs7958415	-0,071	-0,084	0,010	0,017	0,493
<i>GLI1</i>	rs2069506	-0,057	-0,093	0,009	0,017	0,057
<i>USP15</i>	rs11174377	0,070	0,070	0,012	0,021	1,000
<i>ZCCHC8</i>	rs10846978	0,059	0,039	0,011	0,020	0,358
<i>TNFSF11</i>	rs9594751	-0,056	-0,100	0,010	0,018	0,037
<i>LINC00351</i>	rs9531779	-0,058	-0,070	0,009	0,016	0,518
<i>MMP14</i>	rs1042704	-0,068	-0,079	0,011	0,020	0,619
<i>GPR132</i>	rs1022431	-0,091	-0,139	0,017	0,031	0,166
<i>ALDH1A2</i>	rs4646570	0,061	0,104	0,009	0,016	0,018
<i>PPIB</i>	rs148027154	0,250	0,262	0,045	0,067	0,884
<i>SMAD3</i>	rs4776880	-0,103	-0,100	0,009	0,016	0,860
<i>PDE8A</i>	rs11629962	-0,062	-0,089	0,011	0,018	0,190
<i>GAN</i>	rs2966084	-0,063	-0,068	0,010	0,017	0,813
<i>SOCS7</i>	rs113353816	0,063	0,081	0,011	0,020	0,425
<i>AXIN2</i>	rs16961974	0,054	0,063	0,010	0,017	0,651
Empty	rs12941198	0,059	0,053	0,011	0,019	0,780
<i>DCC</i>	rs6508210	0,073	0,075	0,009	0,016	0,926
<i>CACTIN</i>	rs77733715	0,130	0,187	0,023	0,035	0,171
<i>CRLF1</i>	rs2074177	-0,074	-0,092	0,010	0,019	0,407
<i>DDRGL1</i>	rs11697820	-0,056	-0,054	0,009	0,016	0,920
<i>ETS2</i>	rs111901809	0,049	0,042	0,009	0,016	0,687
<i>OSM</i>	rs2285645	-0,181	-0,244	0,026	0,040	0,192
<i>CHRD1</i>	rs67648651	0,051	0,060	0,008	0,013	0,564

Table S6. FastBAT gene prioritisation results, that we obtained from analysis performed with GCTA software⁹⁰. For loci we used 2MB window and for LD reference we used FinnGen. We considered results with $p_{\text{FASTBAT}} < 5 \times 10^{-8}$ and $p_{\text{GWAS}} < 5 \times 10^{-8}$ significant⁹¹.

Chr	Gene	pFASTBAT	pGWAS	TopSNP
1	FAM72C	1.80416e-08	1.76e-19	chr1_149934520_T_C
1	MTMR11	4.79029e-11	4.54e-17	chr1_149920979_A_G
1	OTUD7B	7.38031e-17	1.76e-19	chr1_149934520_T_C
1	SF3B4	1.83939e-11	4.54e-17	chr1_149920979_A_G
1	SRGAP2D	1.76634e-08	1.76e-19	chr1_149934520_T_C
1	VPS45	8.59157e-12	1.51e-18	chr1_150023307_G_A
1	FAM72C	4.04694e-11	2.18e-15	chr1_198819354_G_C
1	SRGAP2D	4.04694e-11	2.18e-15	chr1_198819354_G_C
2	ANTXR1	1.09116e-15	3.45e-21	chr2_69418633_C_A
2	ARHGAP25	5.51267e-14	7.86e-25	chr2_69322904_T_C
2	BMP10	1.80052e-21	5.64e-25	chr2_69341550_A_G
2	GKN1	7.54269e-18	1.5e-21	chr2_69406431_G_GA
2	GKN2	2.23381e-20	6.31e-25	chr2_69352523_C_G
2	ANTXR1	6.32123e-15	1.99e-19	chr2_69433082_G_A
2	GKN1	2.75363e-17	1.99e-19	chr2_69433082_G_A
2	GKN2	1.58446e-15	1.99e-19	chr2_69433082_G_A
3	AMT	1.5124e-08	9.31e-09	chr3_49498696_T_TTTA
3	BSN	4.84111e-09	1.08e-08	chr3_49629531_C_A
3	DAG1	9.3841e-09	9.31e-09	chr3_49498696_T_TTTA
3	GPX1	4.34351e-09	1.21e-08	chr3_49408664_G_GTATA
3	NICN1	7.8823e-09	9.31e-09	chr3_49498696_T_TTTA
3	RHOA	3.89366e-09	9.31e-09	chr3_49498696_T_TTTA
3	TCTA	5.76385e-09	9.31e-09	chr3_49498696_T_TTTA
6	MOXD1	2.50626e-09	1.36e-10	chr6_132913577_G_A
6	BTN3A2	4.16556e-08	3.27e-09	chr6_26353699_A_G
6	BMP6	8.56593e-11	9.09e-14	chr6_7797607_C_G
7	AGMO	1.50745e-11	6.72e-12	chr7_15344063_A_G
7	JAZF1	4.21504e-08	7.32e-09	chr7_28156794_G_A
7	SHFM1	2.66193e-09	1.18e-11	chr7_95941237_T_C
11	DCDC5	4.8859e-08	3.23e-09	chr11_30877762_C_T
12	KDM2B	4.68808e-08	4.49e-08	chr12_122480161_T_C
12	SOX5	3.0539e-10	3.3e-15	chr12_23821470_G_C
12	KLHL42	1.78641e-09	8.41e-12	chr12_28109762_G_GT
12	MANSC4	1.97722e-09	8.41e-12	chr12_28109762_G_GT
12	MRPS35	7.05575e-09	8.41e-12	chr12_28109762_G_GT
12	PPFIBP1	3.18281e-11	1.07e-13	chr12_27844985_C_T
12	SMCO2	3.30074e-08	1.07e-13	chr12_27844985_C_T
12	KLHL42	1.78641e-09	8.41e-12	chr12_28109762_G_GT
12	MANSC4	1.97722e-09	8.41e-12	chr12_28109762_G_GT
12	MRPS35	7.05575e-09	8.41e-12	chr12_28109762_G_GT
12	HSD17B6	2.42438e-08	2.59e-08	chr12_57608816_C_T
12	MYO1A	5.15097e-09	7.37e-09	chr12_57768302_G_T
12	RDH16	4.13935e-08	1.56e-09	chr12_57749071_C_A
12	SDR9C7	2.48397e-08	1.56e-09	chr12_57749071_C_A
12	TAC3	8.61341e-09	1.56e-09	chr12_57749071_C_A
12	ZBTB39	2.4375e-08	1.56e-09	chr12_57749071_C_A
15	CGNL1	3.63258e-09	5.47e-12	chr15_58050948_G_C
15	LCTL	7.2707e-10	4.6e-13	chr15_67085695_A_G
15	MAP2K1	1.50604e-23	1.05e-28	chr15_67072653_G_A
15	RPL4	1.98261e-30	1.05e-28	chr15_67072653_G_A
15	SCARNA14	2.38228e-08	2.38e-10	chr15_66975565_CG_C
15	SNAPC5	2.68647e-29	1.05e-28	chr15_67072653_G_A
15	TIPIN	1.89533e-08	6.13e-11	chr15_66991209_C_A
15	ZWILCH	5.50651e-22	1.05e-28	chr15_67072653_G_A
17	CASKIN2	1.82154e-09	3.6e-08	chr17_71476022_A_C
17	LLGL2	1.12465e-09	3.6e-08	chr17_71476022_A_C
17	TSEN54	2.68638e-09	3.6e-08	chr17_71476022_A_C
18	ATP8B1	6.87157e-10	3.76e-14	chr18_53170750_C_T
18	NEDD4L	4.54904e-10	7.36e-14	chr18_53344021_T_A
19	IFI30	4.87103e-08	2.98e-08	chr19_18381183_G_A
19	LSM4	1.28778e-09	2.19e-10	chr19_18591691_G_A
19	MPV17L2	1.31597e-08	2.98e-08	chr19_18381183_G_A
19	PDE4C	8.52371e-09	2.98e-08	chr19_18381183_G_A
19	PGPEP1	5.8441e-09	1.03e-12	chr19_18616479_A_G
19	RAB3A	8.4324e-09	2.98e-08	chr19_18381183_G_A
20	C20orf141	1.37456e-08	5.15e-10	chr20_2800795_C_T
20	CPXMI	1.38587e-08	5.15e-10	chr20_2800795_C_T
20	PCED1A	1.32913e-08	5.15e-10	chr20_2800795_C_T
20	TMEM239	1.24452e-08	5.15e-10	chr20_2800795_C_T
20	VPS16	1.23202e-08	5.15e-10	chr20_2800795_C_T

Table S7. We investigated eQTL colocalizations between LSS association signals and gene expression using the 'coloc.abf' function from the R-library coloc⁹². The 'biomaRt' R-library was used to extract genes from Ensembl archives⁹³ within a 1 MB (± 500000) window surrounding each lead variant. Colocalizations were investigated for 754 genes that were available in GTEx. We chose tissues relevant to LSS for analysis, including the tibial nerve, cervical spinal cord, and whole blood. For the selected tissues, data on variant-gene expression associations (GTEx v8) were downloaded from GTExportal⁷. Colocalizations with a posterior probability of ≥ 0.8 for the shared variant (PP4) were deemed significant⁹⁴.

Tissue	Gene id	Gene	PP0	PP1	PP2	PP3	PP4
Whole Blood	ENSG00000198380.12	<i>GFPT1</i>	2.49e-36	1.05e-20	3.17e-17	0.133	0.867
Whole Blood	ENSG00000135913.10	<i>USP37</i>	3.47e-09	6.07e-05	6.15e-06	0.107	0.893
Whole Blood	ENSG00000144580.13	<i>CNOT9</i>	8.89e-42	4.66e-05	1.58e-38	0.082	0.918
Whole Blood	ENSG00000178467.17	<i>P4HTM</i>	3.9e-05	0.049	9.93e-05	0.123	0.829
Whole Blood	ENSG00000164062.12	<i>APEH</i>	3.73e-05	3.58e-05	0.085	0.08	0.835
Whole Blood	ENSG00000173531.15	<i>MST1</i>	0.001	0.022	0.006	0.095	0.875
Whole Blood	ENSG00000197409.7	<i>HIST1H3D</i>	0.000363	0.000388	0.008	0.008	0.984
Whole Blood	ENSG00000276966.2	<i>HIST1H4E</i>	7.21e-05	2.55e-05	0.013	0.004	0.983
Whole Blood	ENSG00000124549.14	<i>BTN2A3P</i>	0.005	0.01	0.032	0.06	0.891
Whole Blood	ENSG00000204610.12	<i>TRIM15</i>	1.02e-06	0.004	4.58e-05	0.19	0.806
Whole Blood	ENSG00000228022.5	<i>HCG20</i>	1.43e-08	3.63e-06	3.73e-05	0.008	0.991
Whole Blood	ENSG00000137310.11	<i>TCF19</i>	4.87e-25	2.55e-09	2.21e-17	0.115	0.885
Whole Blood	ENSG00000204472.12	<i>AIF1</i>	3.03e-11	0.016	3.61e-11	0.018	0.967
Whole Blood	ENSG00000247934.4	<i>RP11-967K21.1</i>	2.08e-06	0.004	4.78e-05	0.08	0.917
Whole Blood	ENSG00000123427.16	<i>METTL21B</i>	2.81e-81	1.71e-05	1.12e-77	0.068	0.932
Whole Blood	ENSG00000123297.17	<i>TSFM</i>	5.98e-06	1.48e-05	0.018	0.044	0.939
Whole Blood	ENSG00000033030.13	<i>ZCCHC8</i>	0.037	0.018	0.03	0.014	0.9
Whole Blood	ENSG00000111011.17	<i>RSRC2</i>	2.04e-07	0.000427	6.97e-05	0.145	0.855
Whole Blood	ENSG00000150967.17	<i>ABCY9</i>	7.04e-05	0.015	0.00061	0.128	0.856
Whole Blood	ENSG00000129562.10	<i>DAD1</i>	2.09e-13	0.179	4.71e-15	0.003	0.818
Whole Blood	ENSG00000172590.18	<i>MRPL52</i>	2.35e-10	2.37e-06	5.07e-07	0.004	0.996
Whole Blood	ENSG00000108370.16	<i>RGS9</i>	0.076	0.072	0.017	0.016	0.818
Whole Blood	ENSG00000183397.5	<i>TEKTI1</i>	2.06e-18	0.127	4.21e-19	0.025	0.848
Whole Blood	ENSG00000130517.13	<i>PGPEP1</i>	1.13e-12	0.000281	1.76e-10	0.043	0.957
Whole Blood	ENSG00000105655.18	<i>ISYNA1</i>	0.001	0.025	0.008	0.136	0.83
Whole Blood	ENSG00000132670.20	<i>PTPRA</i>	0.000581	0.004	0.007	0.048	0.941
Whole Blood	ENSG00000255568.3	<i>BRWD1-AS2</i>	3.61e-08	0.000268	1.22e-05	0.09	0.91
Whole Blood	ENSG00000205581.10	<i>HMGNI</i>	0.00033	0.028	0.002	0.16	0.81
Cells_Cultured_fibroblasts	ENSG00000270882.2	<i>HIST2H4A</i>	6.39e-05	2.08e-06	0.11	0.003	0.887
Cells_Cultured_fibroblasts	ENSG00000261716.1	<i>RP11-196G18.22</i>	8.45e-16	4.4e-14	0.003	0.176	0.821
Cells_Cultured_fibroblasts	ENSG00000014914.20	<i>MTMR11</i>	1.7e-11	4.18e-09	5.98e-06	0.000471	1
Cells_Cultured_fibroblasts	ENSG00000135913.10	<i>USP37</i>	5.09e-06	6.28e-05	0.009	0.108	0.883
Cells_Cultured_fibroblasts	ENSG00000115556.13	<i>PLCD4</i>	1.31e-25	6.42e-05	2.32e-22	0.113	0.887
Cells_Cultured_fibroblasts	ENSG00000115568.15	<i>ZNF142</i>	2.82e-06	7.9e-05	0.005	0.137	0.858
Cells_Cultured_fibroblasts	ENSG00000178467.17	<i>P4HTM</i>	1.31e-26	0.046	3.78e-26	0.132	0.822
Cells_Cultured_fibroblasts	ENSG00000198218.10	<i>QRCHI</i>	0.026	0.062	0.027	0.063	0.823
Cells_Cultured_fibroblasts	ENSG00000235908.1	<i>RHOA-IT1</i>	6.28e-06	3.23e-05	0.02	0.101	0.879
Cells_Cultured_fibroblasts	ENSG00000164330.16	<i>EBF1</i>	6.73e-05	0.003	0.001	0.047	0.949
Cells_Cultured_fibroblasts	ENSG00000145860.11	<i>RNF145</i>	0.037	0.019	0.047	0.023	0.874
Cells_Cultured_fibroblasts	ENSG00000228022.5	<i>HCG20</i>	1.04e-21	3.18e-06	3.55e-18	0.01	0.99
Cells_Cultured_fibroblasts	ENSG00000204314.10	<i>PRT1</i>	2.49e-05	0.01	8.27e-05	0.032	0.957
Cells_Cultured_fibroblasts	ENSG00000221988.12	<i>PPT2</i>	4.09e-05	0.024	0.000144	0.083	0.894
Cells_Cultured_fibroblasts	ENSG00000204308.7	<i>RNF5</i>	2.02e-07	0.004	9.91e-06	0.195	0.801
Cells_Cultured_fibroblasts	ENSG00000204305.13	<i>AGER</i>	1.27e-11	0.007	9.08e-11	0.047	0.947
Cells_Cultured_fibroblasts	ENSG00000204301.6	<i>NOTCH4</i>	2.25e-08	2.39e-08	0.081	0.085	0.833
Cells_Cultured_fibroblasts	ENSG00000204287.13	<i>HLA-DRA</i>	0.003	0.000956	0.041	0.011	0.944
Cells_Cultured_fibroblasts	ENSG00000179912.20	<i>R3HDM2</i>	0.015	0.071	0.016	0.074	0.824
Cells_Cultured_fibroblasts	ENSG00000111012.9	<i>CYP27B1</i>	7.03e-08	1.36e-05	0.000277	0.052	0.947
Cells_Cultured_fibroblasts	ENSG00000123427.16	<i>METTL21B</i>	2.54e-152	1.62e-05	1.02e-148	0.064	0.936
Cells_Cultured_fibroblasts	ENSG00000123297.17	<i>TSFM</i>	8.3e-208	1.39e-05	3.32e-204	0.055	0.945
Cells_Cultured_fibroblasts	ENSG00000245651.2	<i>RP11-620J15.2</i>	0.001	0.000443	0.055	0.017	0.926
Cells_Cultured_fibroblasts	ENSG00000273805.1	<i>RP11-620J15.4</i>	0.038	0.025	0.043	0.028	0.866
Cells_Cultured_fibroblasts	ENSG00000023516.8	<i>AKAP11</i>	0.00029	0.004	0.002	0.023	0.971
Cells_Cultured_fibroblasts	ENSG00000129562.10	<i>DAD1</i>	0.013	0.09	0.000211	0.000525	0.896
Cells_Cultured_fibroblasts	ENSG00000157227.12	<i>MMP14</i>	0.000106	0.01	8.56e-05	0.007	0.982
Cells_Cultured_fibroblasts	ENSG00000137834.14	<i>SMAD6</i>	0.022	0.012	0.036	0.019	0.911
Cells_Cultured_fibroblasts	ENSG00000276170.4	<i>AC124789.1</i>	0.000557	0.000869	0.011	0.016	0.971
Cells_Cultured_fibroblasts	ENSG00000183397.5	<i>TEKTI1</i>	8.19e-05	0.099	5.73e-06	0.006	0.895

Cells_Cultured_fibroblasts	ENSG00000130513.6	<i>GDF15</i>	0.02	0.018	0.01	0.008	0.945
Cells_Cultured_fibroblasts	ENSG00000088882.7	<i>CPXMI</i>	3.56e-08	1.99e-05	4.03e-05	0.022	0.978
Cells_Cultured_fibroblasts	ENSG00000235701.1	<i>PCBP2P1</i>	4.08e-06	0.000411	0.002	0.158	0.84
Cells_Cultured_fibroblasts	ENSG00000255568.3	<i>BRWDI-AS2</i>	5.96e-08	0.000261	1.76e-05	0.076	0.924
Nerve_Tibial	ENSG00000014914.20	<i>MTMR11</i>	7.07e-09	2.44e-08	0.003	0.008	0.99
Nerve_Tibial	ENSG00000081237.18	<i>PTPRC</i>	6.97e-07	1.34e-06	0.046	0.087	0.867
Nerve_Tibial	ENSG00000169604.19	<i>ANTXR1</i>	1.35e-09	5.23e-09	0.023	0.088	0.889
Nerve_Tibial	ENSG00000169599.12	<i>NFU1</i>	6.43e-23	8.79e-21	0.000817	0.111	0.888
Nerve_Tibial	ENSG00000135913.10	<i>USP37</i>	6.18e-13	0.000103	1.1e-09	0.181	0.819
Nerve_Tibial	ENSG00000115556.13	<i>PLCD4</i>	1.74e-07	9.02e-05	0.000302	0.156	0.844
Nerve_Tibial	ENSG00000115568.15	<i>ZNF142</i>	1.13e-05	0.005	0.000303	0.143	0.852
Nerve_Tibial	ENSG00000270441.1	<i>RP11-694I15.7</i>	0.002	0.055	0.003	0.067	0.873
Nerve_Tibial	ENSG00000164062.12	<i>APEH</i>	5.48e-10	5.6e-05	1.77e-06	0.18	0.82
Nerve_Tibial	ENSG00000164171.10	<i>ITGA2</i>	5.77e-06	0.009	1.34e-05	0.021	0.97
Nerve_Tibial	ENSG00000239264.8	<i>TXNDC5</i>	1.76e-10	0.021	1.69e-10	0.019	0.96
Nerve_Tibial	ENSG00000228022.5	<i>HCG20</i>	2.56e-16	3.15e-06	6.7e-13	0.007	0.993
Nerve_Tibial	ENSG00000168631.12	<i>DPCR1</i>	8.79e-24	0.001	9.55e-22	0.117	0.882
Nerve_Tibial	ENSG00000204498.10	<i>NFKBIL1</i>	2.49e-05	2.33e-05	0.006	0.005	0.989
Nerve_Tibial	ENSG00000204472.12	<i>AFI</i>	0.075	0.036	0.019	0.008	0.861
Nerve_Tibial	ENSG00000204256.12	<i>BRD2</i>	1.83e-05	0.005	0.000553	0.138	0.857
Nerve_Tibial	ENSG00000111816.7	<i>FRK</i>	0.001	0.004	0.012	0.047	0.936
Nerve_Tibial	ENSG00000200534.1	<i>SNORA33</i>	0.009	0.051	0.015	0.079	0.846
Nerve_Tibial	ENSG00000187546.13	<i>AGMO</i>	0.007	0.001	0.091	0.012	0.889
Nerve_Tibial	ENSG00000153814.11	<i>JAZF1</i>	1.05e-10	5.59e-05	5.79e-08	0.03	0.97
Nerve_Tibial	ENSG00000066382.16	<i>MPPED2</i>	2.24e-06	2.48e-05	0.012	0.132	0.856
Nerve_Tibial	ENSG00000166908.17	<i>PIP4K2C</i>	0.000103	0.000483	0.014	0.063	0.923
Nerve_Tibial	ENSG00000135506.15	<i>OS9</i>	0.000573	0.021	0.004	0.142	0.832
Nerve_Tibial	ENSG00000135452.9	<i>TSPAN31</i>	1.04e-05	1.65e-05	0.03	0.047	0.923
Nerve_Tibial	ENSG00000135446.16	<i>CDK4</i>	1.61e-05	0.000158	0.013	0.128	0.858
Nerve_Tibial	ENSG00000111012.9	<i>CYP27B1</i>	2.31e-06	1.51e-05	0.008	0.051	0.941
Nerve_Tibial	ENSG00000123427.16	<i>METTL21B</i>	9.51e-57	1.64e-05	3.81e-53	0.065	0.935
Nerve_Tibial	ENSG00000123297.17	<i>TSM</i>	6.28e-21	1.25e-05	2.52e-17	0.049	0.951
Nerve_Tibial	ENSG00000033030.13	<i>ZCCHC8</i>	0.013	0.002	0.056	0.009	0.92
Nerve_Tibial	ENSG00000184445.11	<i>KNTC1</i>	2.37e-06	0.091	5.68e-07	0.021	0.888
Nerve_Tibial	ENSG00000103657.13	<i>HERC1</i>	0.043	0.099	0.004	0.009	0.845
Nerve_Tibial	ENSG00000259347.6	<i>RP11-798K3.2</i>	2.77e-12	5.79e-13	0.043	0.008	0.949
Nerve_Tibial	ENSG00000105325.13	<i>FZR1</i>	2.73e-18	0.097	6.55e-19	0.022	0.88
Nerve_Tibial	ENSG00000183397.5	<i>TEKTIP1</i>	1.33e-27	0.14	3.81e-28	0.039	0.821
Nerve_Tibial	ENSG00000255568.3	<i>BRWDI-AS2</i>	1.56e-07	0.00034	4.6e-05	0.099	0.9
Brain_Spinal_cord_cervical_c-1	ENSG00000178467.17	<i>PAHTM</i>	5.38e-07	0.051	1.5e-06	0.141	0.808
Brain_Spinal_cord_cervical_c-1	ENSG00000178252.17	<i>WDR6</i>	2.72e-05	0.055	6.69e-05	0.133	0.812
Brain_Spinal_cord_cervical_c-1	ENSG00000243753.5	<i>HLA-L</i>	0.016	0.063	0.015	0.059	0.846
Brain_Spinal_cord_cervical_c-1	ENSG00000228022.5	<i>HCG20</i>	2.64e-08	3.28e-06	0.000102	0.012	0.988
Brain_Spinal_cord_cervical_c-1	ENSG00000168631.12	<i>DPCR1</i>	0.002	0.002	0.054	0.07	0.872
Brain_Spinal_cord_cervical_c-1	ENSG00000196260.4	<i>SFTA2</i>	4.26e-11	0.002	1.34e-09	0.059	0.939
Brain_Spinal_cord_cervical_c-1	ENSG00000137310.11	<i>TCF19</i>	1.99e-09	3.82e-09	0.058	0.11	0.832
Brain_Spinal_cord_cervical_c-1	ENSG00000206344.7	<i>HCG27</i>	2.45e-07	3.37e-07	0.056	0.076	0.868
Brain_Spinal_cord_cervical_c-1	ENSG00000204525.16	<i>HLA-C</i>	1.61e-18	1.28e-06	1.29e-13	0.102	0.898
Brain_Spinal_cord_cervical_c-1	ENSG00000204308.7	<i>RNF5</i>	0.004	0.003	0.052	0.043	0.898
Brain_Spinal_cord_cervical_c-1	ENSG00000111816.7	<i>FRK</i>	0.024	0.085	0.005	0.017	0.868
Brain_Spinal_cord_cervical_c-1	ENSG00000231023.6	<i>LINC00326</i>	0.007	0.003	0.06	0.021	0.909
Brain_Spinal_cord_cervical_c-1	ENSG00000247934.4	<i>RP11-967K21.1</i>	0.000392	0.013	0.004	0.117	0.866
Brain_Spinal_cord_cervical_c-1	ENSG00000123427.16	<i>METTL21B</i>	2.7e-14	1.61e-05	1.06e-10	0.062	0.938
Brain_Spinal_cord_cervical_c-1	ENSG00000270039.1	<i>RP11-571M6.17</i>	0.041	0.016	0.058	0.022	0.862
Brain_Spinal_cord_cervical_c-1	ENSG00000073417.14	<i>PDE8A</i>	0.001	0.003	0.032	0.081	0.882
Brain_Spinal_cord_cervical_c-1	ENSG00000183527.11	<i>PSMG1</i>	2.85e-10	0.000245	1.1e-07	0.094	0.905
Brain_Spinal_cord_cervical_c-1	ENSG00000255568.3	<i>BRWDI-AS2</i>	0.000527	0.000327	0.023	0.013	0.963

Table S8. Calculated cumulative morbidities and surgery rates for every LSS-associated variant. We also calculated age when the curve of the effect allele (EA) homozygotes statistically differed from the curve of other allele (OA) homozygotes of the same variant (AGE (pval)). Following formula was utilised: $diff = ('survival\ rate\ EA/EA' - 'survival\ rate\ OA/OA') / \sqrt{('se_survival\ rate\ EA/EA^2' + 'se_survival\ rate\ OA/OA^2')}$, $p = 2 * (1 - diff)$. $P < 0.05$ was used as the threshold for a significant difference. -, no significant difference between the homozygotes.

Candidate Gene	rsid	EA	OA	AGE (pval)	Cum. Morb. EA	Cum. Morb. OA	Cum. Surg. EA	Cum. Surg. OA
RUNX3	rs9438857	G	A	54 ($p=0.006$)	6.1%	6.6%	2.7%	3.1%
NGF	rs6327	T	C	54 ($p=0.005$)	6.1%	6.7%	2.8%	3.2%
OTUD7B	rs11205303	C	T	40 ($p=1.82e-06$)	5.8%	6.6%	2.6%	3.2%
ZNF687	rs147042690	T	C	-	11.6%	6.5%	5.4%	3.1%
PTPRC	rs72739729	C	G	57 ($p=0.03$)	5.7%	6.6%	2.6%	3.1%
GFPT1	rs4340572	G	A	44 ($p=0.0004$)	6.1%	6.7%	2.8%	3.2%
USP37	rs60362609	G	C	40 ($p=0.001$)	6.2%	6.8%	2.9%	3.2%
DAG1	rs138073019	TTTA	T	72 ($p=0.004$)	6.4%	6.6%	3.0%	3.1%
RAB28	rs3057070	A	AGAG	61 ($p=0.01$)	6.0%	6.6%	2.7%	3.1%
DAB2	rs148346348	ATATG	A	48 ($p=0.01$)	7.8%	6.5%	4.0%	3.1%
ITGA2	rs11747379	A	C	52 ($p=0.049$)	7.1%	6.5%	3.4%	3.1%
EBF1	rs200608668	G	GC	-	6.9%	6.5%	3.1%	3.1%
BMP6	rs10498672	G	C	55 ($p=0.0004$)	7.3%	6.5%	3.8%	3.1%
TRIM38	rs9358913	G	A	61 ($p=0.02$)	6.3%	6.6%	2.9%	3.1%
HLA	rs62390186	A	T	-	6.1%	6.6%	2.9%	3.1%
HLA	rs4294047	A	G	-	6.1%	6.6%	2.9%	3.1%
HLA	rs17205170	T	G	54 ($p=0.02$)	6.0%	6.6%	2.7%	3.1%
CDC3L	rs7770012	A	C	40 ($p=1.52e-06$)	6.8%	6.4%	3.3%	3.0%
LIN28B	rs314261	C	A	50 ($p=0.03$)	6.8%	6.4%	3.3%	3.0%
COL10A1	rs7739896	G	A	53 ($p=0.0003$)	6.3%	6.6%	2.9%	3.1%
EYA4	rs2764217	A	G	50 ($p=0.03$)	7.1%	6.4%	3.3%	3.0%
FOXK1	rs28658109	C	T	46 ($p=0.02$)	5.8%	6.6%	2.7%	3.1%
AGMO	rs75674922	G	A	54 ($p=0.03$)	7.8%	6.5%	3.8%	3.1%
TWIST1	rs2390116	T	C	62 ($p=0.02$)	6.3%	6.6%	2.9%	3.1%
JAZF1	rs849135	A	G	45 ($p=0.001$)	6.1%	6.7%	2.8%	3.2%
Empty	rs139203647	G	GT	63 ($p=0.02$)	7.7%	6.5%	3.9%	3.1%
DYNC111	rs11769842	C	T	57 ($p=0.005$)	6.8%	6.2%	3.2%	2.9%
MKX	rs2637326	T	G	47 ($p=0.008$)	6.8%	6.5%	3.1%	3.1%
MPPED2	rs607165	C	T	55 ($p=0.001$)	6.9%	6.4%	3.3%	3.0%
PDE3A	rs73067286	A	T	52 ($p=0.004$)	5.8%	6.6%	2.8%	3.1%
SOX5	rs12308843	C	G	40 ($p=0.0001$)	7.0%	6.5%	3.4%	3.1%
CCDC91	rs7958415	T	C	46 ($p=0.005$)	5.8%	6.6%	2.6%	3.1%
GLI1	rs2069506	A	C	66 ($p=0.03$)	6.2%	6.6%	2.9%	3.1%
USP15	rs11174377	A	G	57 ($p=0.01$)	7.0%	6.5%	3.3%	3.1%
ZCCHC8	rs10846978	C	T	-	6.4%	6.6%	3.1%	3.0%
TNFSF11	rs9594751	T	C	43 ($p=0.002$)	5.8%	6.6%	2.5%	3.1%
SLITRK6	rs9531779	G	C	55 ($p=0.002$)	6.3%	6.6%	3.0%	3.1%
MMP14	rs1042704	A	G	51 ($p=0.008$)	5.9%	6.6%	2.7%	3.1%
GPR132	rs1022431	A	C	-	6.1%	6.6%	2.8%	3.1%
ALDH1A2	rs4646570	C	G	56 ($p=0.002$)	7.0%	6.4%	3.5%	3.0%
PPIB	rs148027154	A	T	-	8.1%	6.5%	6.3%	3.1%
SMAD3	rs4776880	A	G	40 ($p=6.58e-06$)	6.0%	6.6%	2.8%	3.1%
PDE8A	rs11629962	T	C	54 ($p=0.01$)	6.0%	6.6%	2.9%	3.1%
GAN	rs2966084	G	A	56 ($p=0.01$)	6.3%	6.8%	3.0%	3.2%
SOCS7	rs113353816	C	T	63 ($p=0.04$)	6.7%	6.4%	3.1%	3.0%
AXIN2	rs16961974	C	T	70 ($p=0.03$)	6.8%	6.5%	3.2%	3.1%
Empty	rs12941198	C	A	62 ($p=0.03$)	6.8%	6.2%	3.2%	2.9%
DCC	rs6508210	C	A	45 ($p=0.001$)	6.9%	6.4%	3.2%	3.0%
CACTIN	rs77733715	G	A	-	9.2%	6.5%	4.7%	3.1%
CRLF1	rs2074177	G	A	65 ($p=0.03$)	6.0%	6.6%	2.8%	3.1%
DDRGK1	rs11697820	T	C	65 ($p=0.04$)	6.3%	6.7%	3.0%	3.1%
ETS2	rs111901809	T	TAGAGGGGCAGGGGGCG	47 ($p=0.004$)	6.8%	6.4%	3.2%	3.0%
OSM	rs2285645	T	C	-	4.4%	6.6%	2.0%	3.1%

Table S9. Genetic correlations between 517 traits and LSS. LDSC-software⁹⁵, was utilised for calculation of the correlations. Traits were extracted from the GWAS database provided by the MRC Integrative Epidemiology Unit (IEU). rg, genetic correlation coefficient value; se, standard error; pFDR, false discovery rate-corrected p-value.

Trait	GWAS-ID	rg	se	pFDR
Diagnoses - main ICD-10: M54 Dorsalgia	ukb-a-569	0.7543	0.06612	7.40e-29
Main ICD-10: M25 Other joint disorders, not elsewhere classified	ukb-d-M25	0.7229	0.1138	1.21e-09
Back pain	ukb-b-9838	0.6031	0.02683	5.05e-109
Leg pain on walking	ukb-b-10387	0.5652	0.04453	1.89e-35
Hip pain	ukb-b-7289	0.5482	0.03365	1.24e-57
Main ICD-10: M70 Soft tissue disorders related to use, overuse, and pressure	ukb-d-M70	0.5014	0.223	0.041
Back pain for 3+ months	ukb-b-8463	0.4958	0.05587	6.79e-18
Main ICD-10: T84 Complications of internal orthopaedic prosthetic devices, implants, and grafts	ukb-d-T84	0.4859	0.08538	5.54e-08
Diagnoses - main ICD-10: J22 Unspecified acute lower respiratory infection	ukb-b-8707	0.4761	0.381	0.278
Diagnoses - main ICD-10: K30 Dyspepsia	ukb-b-14814	0.468	0.1135	0.0001
Number of operations, self-reported	ukb-b-4733	0.458	0.02828	5.38e-57
Neck/shoulder pain for 3+ months	ukb-b-16118	0.4546	0.06353	5.56e-12
Neck or shoulder pain	ukb-b-18596	0.454	0.02897	1.97e-53
Taking other prescription medications	ukb-b-20292	0.4506	0.03005	6.10e-49
Diagnoses - main ICD-10: I20 Angina pectoris	ukb-a-532	0.4443	0.07324	6.50e-09
Diagnoses - main ICD-10: R07 Pain in throat and chest	ukb-a-581	0.4412	0.04621	1.56e-20
Major depressive disorder (ICD-10 coded)	ebi-a-GCST005903	0.4358	0.05246	8.26e-16
Long-standing illness, disability, or infirmity	ukb-b-13764	0.4352	0.02657	3.39e-58
Number of treatments/medications taken	ukb-b-3656	0.4345	0.0243	4.26e-69
Chest pain or discomfort walking normally	ukb-b-11578	0.4327	0.0557	6.08e-14
Had major operations	ukb-b-9937	0.4275	0.05072	3.13e-16
Diagnoses - main ICD-10: J34 Other disorders of nose and nasal sinuses	ukb-a-542	0.4241	0.1592	0.014
Diagnoses - main ICD-10: R11 Nausea and vomiting	ukb-b-19419	0.4234	0.1708	0.023
Pain all over the body	ukb-a-477	0.4129	0.05168	1.08e-14
Diagnoses - main ICD-10: G56 Mononeuropathies of upper limb	ukb-a-528	0.4106	0.05256	4.39e-14
Diagnoses - main ICD-10: R10 Abdominal and pelvic pain	ukb-a-582	0.4106	0.05693	3.85e-12
Why reduced smoking: Illness or ill health	ukb-b-9930	0.4094	0.1838	0.043
Why reduced smoking: Doctor's advice	ukb-b-17579	0.4067	0.2977	0.232
Overall health rating	ukb-b-6306	0.4047	0.02328	2.25e-65
Medication for pain relief, constipation, heartburn: Laxatives	ukb-b-11461	0.4041	0.04579	1.05e-17
Diagnoses - main ICD-10: K29 Gastritis and duodenitis	ukb-a-547	0.4025	0.06778	1.36e-08
Medication for pain relief, constipation, heartburn: Omeprazole	ukb-b-11605	0.3988	0.0431	2.39e-19
Lumbar spine bone mineral density	ieu-a-982	0.3955	0.04694	3.18e-16
Diagnoses - main ICD-10:R35 Polyuria	ukb-b-5948	0.393	0.1248	0.003
Diagnoses - main ICD-10: K52 Other non-infective gastro-enteritis and colitis	ukb-a-554	0.3914	0.09023	4.20e-05
Knee pain	ukb-b-16254	0.384	0.03448	1.40e-27
Diagnoses - main ICD-10: R69 Unknown and unspecified causes of morbidity	ukb-b-12510	0.3832	0.09176	8.24e-05
Knee pain for 3+ months	ukb-b-8906	0.3828	0.08275	1.15e-05
Illness, injury, bereavement, stress in the last 2 years: Serious illness, injury, or assault to yourself	ukb-b-18162	0.3817	0.04249	2.63e-18
Health satisfaction	ukb-b-2053	0.3817	0.03248	1.51e-30
Ever had hysterectomy (womb removed)	ukb-b-6445	0.3769	0.05241	4.32e-12
Diagnoses - main ICD-10: M24 Other specific joint derangements	ukb-a-567	0.3766	0.1149	0.002
Diagnoses - main ICD-10: M21 Other acquired deformities of limbs	ukb-a-565	0.3727	2.404	0.894
Vascular/heart problems diagnosed by doctor: Angina	ukb-b-8468	0.3713	0.03715	2.17e-22
Diagnoses - main ICD-10: M17 Gonarthrosis [arthrosis of knee]	ukb-a-563	0.3702	0.05174	5.56e-12
Had other major operations	ukb-b-15378	0.3677	0.037	3.71e-22
Reason for reducing amount of alcohol drunk: Illness or ill health	ukb-d-2664_1	0.3568	0.1052	0.002
Diagnoses - main ICD-10: G47 Sleep disorders	ukb-a-527	0.3524	0.07514	8.56e-06
Medication for pain relief, constipation, heartburn: Ranitidine	ukb-b-8146	0.3468	0.07108	3.50e-06
Diagnoses - main ICD-10: K62 Other diseases of anus and rectum	ukb-a-557	0.3413	0.08907	0.0003
Ever used hormone-replacement therapy (HRT)	ukb-b-18541	0.3382	0.0357	3.01e-20
Frequency of tiredness/lethargy in last 2 weeks	ukb-b-929	0.3381	0.02681	4.86e-35
Alcohol drinker status: Previous	ukb-a-227	0.3362	0.04852	2.70e-11
Medication for pain relief, constipation, heartburn: Paracetamol	ukb-b-17595	0.3308	0.02845	6.42e-30
Other serious medical condition/disability diagnosed by doctor	ukb-b-14961	0.3305	0.03341	5.74e-22
Ever highly irritable/argumentative for 2 days	ukb-b-8196	0.3302	0.04128	1.01e-14
Shortness of breath walking on level ground	ukb-b-9543	0.3279	0.04709	2.14e-11
Diagnoses - main ICD-10: M16 Coxarthrosis [arthrosis of hip]	ukb-a-562	0.3266	0.0535	5.17e-09
Emphysema/chronic bronchitis	ukb-b-16207	0.325	0.05243	2.97e-09

Diagnoses - main ICD-10: M67 Other disorders of synovium and tendon	ukb-a-570	0.322	0.1519	0.055
Frequency of depressed mood in last 2 weeks	ukb-b-3822	0.3216	0.03533	8.91e-19
Falls in the last year	ukb-b-2535	0.3212	0.03005	1.74e-25
Medication for pain relief, constipation, heartburn: Ibuprofen	ukb-b-8888	0.3184	0.03733	1.35e-16
Childhood asthma (age<16)	ukb-d- ASTHMA CHILD	0.3152	0.08253	0.0003
Diagnoses - main ICD-10: I25 Chronic ischemic heart disease	ukb-a-534	0.3118	0.04279	2.26e-12
Chest pain or discomfort	ukb-b-10591	0.3109	0.02984	2.87e-24
Frequency of unenthusiasm/disinterest in the last 2 weeks	ukb-b-1419	0.3097	0.03351	2.60e-19
Seen doctor (GP) for nerves, anxiety, tension, or depression	ukb-b-6991	0.3076	0.02706	1.12e-28
Diagnoses - main ICD-10: M23 Internal derangement of knee	ukb-a-566	0.3066	0.08106	0.0004
Adopted as a child	ukb-b-13183	0.3047	0.06779	2.11e-05
Diagnoses - main ICD-10: K21 Gastro-oesophageal reflux disease	ukb-a-545	0.3	0.07126	7.16e-05
Transport type for commuting to workplace: Car/motor vehicle	ukb-b-11025	0.2998	0.045	1.66e-10
Frequency of tenseness/restlessness in last 2 weeks	ukb-b-5664	0.2979	0.03016	6.48e-22
Leg fat mass (left)	ukb-b-7212	0.2976	0.02046	3.97e-46
Leg fat mass (right)	ukb-b-18096	0.2957	0.02056	3.96e-45
Coronary artery disease	ebi-a-GCST005195	0.294	0.02842	6.17e-24
Body mass index (BMI)	ukb-b-19953	0.2928	0.01999	9.76e-47
Number of children fathered	ukb-b-2227	0.2927	0.04045	3.24e-12
Bilateral oophorectomy (both ovaries removed)	ukb-a-325	0.2926	0.05574	5.88e-07
Medication for pain relief, constipation, heartburn: Aspirin	ukb-b-7137	0.292	0.034	8.31e-17
Mood swings	ukb-b-14180	0.2895	0.02826	1.67e-23
Wheeze or whistling in the chest in the last year	ukb-b-18335	0.2885	0.03027	1.76e-20
Vascular/heart problems diagnosed by doctor: Heart attack	ukb-b-11590	0.2884	0.04347	1.95e-10
Sleeplessness/insomnia	ukb-b-3957	0.2881	0.02539	1.38e-28
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Hormone replacement therapy	ukb-b-8080	0.2878	0.0591	3.68e-06
Diagnoses - main ICD-10: Z09 Follow-up examination after treatment for conditions other than malignant neoplasms	ukb-a-594	0.2853	0.1064	0.013
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Cholesterol lowering medication	ukb-b-17805	0.285	0.03933	3.03e-12
Maternal smoking around birth	ukb-b-17685	0.2835	0.02901	1.79e-21
Noisy workplace	ukb-b-2091	0.2834	0.03983	7.40e-12
Waist circumference	ukb-b-9405	0.2818	0.02043	1.61e-41
Diagnoses - main ICD-10: J44 Other chronic obstructive pulmonary disease	ukb-a-543	0.279	0.09043	0.0039943
Former alcohol drinker	ukb-b-12654	0.279	0.05559	1.82e-06
Diagnoses - main ICD-10: J45.9 Asthma, unspecified	ukb-b-20208	0.2786	0.1467	0.087
Ever had bowel cancer screening	ukb-b-17001	0.2772	0.04815	3.83e-08
Vitamin and mineral supplements: Vitamin B	ukb-b-10188	0.2771	0.05369	9.11e-07
Diagnoses - main ICD-10: K20 Oesophagitis	ukb-b-19354	0.2766	0.09267	0.005
Weight	ukb-b-11842	0.2762	0.02042	4.90e-40
Main ICD-10: N92 Excessive , frequent, and irregular menstruation	ukb-d-N92	0.2752	0.06264	3.30e-05
Operation code: bilateral oophorectomy	ukb-b-1962	0.2741	0.05391	1.34e-06
Arm fat-free mass (left)	ukb-b-19925	0.2726	0.02016	4.90e-40
Bring up phlegm/sputum/mucus on most days	ukb-b-12841	0.2719	0.06711	0.0001
Arm fat-free mass (right)	ukb-b-19520	0.2711	0.0199	1.39e-40
Major coronary heart disease event	ukb-d-I9 CHD	0.268	0.04379	4.77e-09
Leg fat percentage	ukb-b-18377	0.2678	0.02094	6.06e-36
Arm fat mass (right)	ukb-b-6704	0.2678	0.02024	1.91e-38
Arm fat mass (left)	ukb-b-8338	0.2676	0.0205	2.14e-37
Depressive symptoms	ieu-a-1000	0.2674	0.04703	5.68e-08
Fed-up feelings	ukb-b-19809	0.2673	0.02992	4.03e-18
Blood clot in the lung	ukb-b-13704	0.2668	0.0736	0.0006
Stomach or abdominal pain	ukb-b-11413	0.2667	0.04577	2.56e-08
Diagnoses - main ICD-10: R04 Haemorrhage from respiratory passages	ukb-a-580	0.2656	0.1251	0.054
Whole body fat mass	ukb-b-19393	0.2642	0.02067	6.47e-36
Smoking status: Current	ukb-a-225	0.2626	0.03102	2.25e-16
Diagnoses - secondary ICD-10: M06.99 Rheumatoid arthritis, unspecified (Site unspecified)	ukb-b-11874	0.2622	0.08531	0.004
Diagnoses - main ICD-10: K43 Ventral hernia	ukb-a-550	0.2605	0.07408	0.001
Leg fat percentage (right)	ukb-b-20531	0.2592	0.02091	7.00e-34
Pack years of smoking	ukb-b-10831	0.2577	0.03279	3.03e-14
Pulse wave arterial stiffness index	ukb-b-11971	0.2573	0.04611	1.00e-07
Ever stopped smoking for 6+ months	ukb-b-11355	0.2542	0.08089	0.003
Hip circumference	ukb-b-15590	0.2531	0.01998	2.49e-35
Smoking/smokers in household	ukb-b-960	0.253	0.04618	1.77e-07
Qualifications: None of the above	ukb-b-17729	0.2525	0.02252	6.24e-28
Basal metabolic rate	ukb-b-16446	0.2518	0.02022	3.54e-34

Loneliness, isolation	ukb-b-8476	0.25	0.03266	1.46e-13
Other eye problems	ukb-b-7007	0.2495	0.04843	9.49e-07
Illness, injury, bereavement, stress in the last 2 years: Financial difficulties	ukb-b-9667	0.2484	0.03138	1.94e-14
Ever had stillbirth, spontaneous miscarriage, or termination	ukb-b-12621	0.2474	0.04761	7.63e-07
Smoking initiation	ieu-b-4877	0.2471	0.0211	2.31e-30
Type 2 diabetes	ebi-a-GCST006867	0.2469	0.02953	5.53e-16
Mouth/teeth dental problems: Toothache	ukb-b-19191	0.2447	0.06593	0.0005
Job involves shift work	ukb-b-1712	0.2445	0.04163	1.99e-08
Blood clot in the leg (DVT)	ukb-b-11411	0.2417	0.0562	4.87e-05
Trunk fat mass	ukb-b-20044	0.2414	0.02109	4.79e-29
Reason for reducing amount of alcohol drunk: Doctor's advice	ukb-d-2664_2	0.2413	0.1144	0.056
Job involves heavy manual or physical work	ukb-b-2002	0.2395	0.02884	8.26e-16
Whole body water mass	ukb-b-14540	0.2394	0.02025	6.92e-31
Diagnoses - main ICD-10: K22 Other diseases of oesophagus	ukb-a-546	0.2383	0.09374	0.019
Whole body fat-free mass	ukb-b-13354	0.2375	0.02024	1.87e-30
Current tobacco smoking	ukb-b-223	0.2367	0.02884	1.84e-15
Childhood obesity	ieu-a-1096	0.2352	0.04796	3.13e-06
Leg fat free-mass (left)	ukb-b-16099	0.2337	0.0206	1.42e-28
Facial pain	ukb-b-17107	0.2337	0.07309	0.003
Diagnoses - main ICD-10: I10 Essential (primary) hypertension	ukb-a-531	0.2335	0.1284	0.102
Diabetes diagnosed by doctor	ukb-b-10753	0.2332	0.03192	2.01e-12
Financial situation satisfaction	ukb-b-2830	0.2328	0.03736	2.47e-09
Extreme waist-to-hip ratio	ieu-a-87	0.2324	0.07126	0.002
Seen a psychiatrist for nerves, anxiety, tension, or depression	ukb-b-18336	0.2322	0.0354	3.15e-10
Average weekly spirits intake	ukb-b-1707	0.2321	0.03499	1.99e-10
Qualifications: NVQ or HND or HNC or equivalent	ukb-b-7926	0.2303	0.03987	3.45e-08
Leg fat-free mass (right)	ukb-b-12828	0.2279	0.02049	1.65e-27
Waist-to-hip ratio	ieu-a-72	0.2278	0.03047	5.64e-13
Diagnoses - main ICD-10: I21 Acute myocardial infarction	ukb-a-533	0.2274	0.06478	0.001
Miserableness	ukb-b-18994	0.227	0.03078	1.20e-12
Trunk fat-free mass	ukb-b-17409	0.2257	0.02043	3.61e-27
Body fat percentage	ukb-b-8909	0.2227	0.02107	5.84e-25
Number of full brothers	ukb-b-4263	0.222	0.04402	1.64e-06
Number of older siblings	ukb-b-1997	0.2196	0.07887	0.010
Vascular/heart problems diagnosed by doctor: Stroke	ukb-b-8714	0.2194	0.07199	0.005
Arm fat percentage (left)	ukb-b-20188	0.2191	0.02083	9.77e-25
Arm fat percentage (right)	ukb-b-12854	0.2182	0.0207	7.95e-25
Ever unenthusiastic/disinterested for a whole week	ukb-b-18674	0.2181	0.03865	7.22e-08
Types of physical activity in last 4 weeks: None of the above	ukb-b-15869	0.2177	0.03735	2.56e-08
Vascular/heart problems diagnosed by doctor: High blood pressure	ukb-b-14177	0.2174	0.02334	1.36e-19
Mouth/teeth dental problems: Dentures	ukb-b-12930	0.2173	0.03016	4.02e-12
Mouth/teeth dental problems: Painful gums	ukb-b-11161	0.217	0.05991	0.0007
Diagnoses - main ICD-10: M20 Acquired deformities of fingers and toes	ukb-a-564	0.2157	0.05354	0.0001
Vitamin and mineral supplements: Vitamin A	ukb-b-9596	0.2145	0.08409	0.019
Diagnoses - main ICD-10: K44 Diaphragmatic hernia	ukb-a-551	0.214	0.07704	0.010
Diagnoses - main ICD-10: R31 Unspecified haematuria	ukb-b-17885	0.2136	0.07223	0.006
Cigarettes smoked per day	ieu-b-142	0.2133	0.03089	3.14e-11
Cigarettes per day	ieu-b-25	0.2133	0.03089	3.14e-11
Diagnoses - main ICD-10: I84 Haemorrhoids	ukb-a-539	0.2131	0.05595	0.0003
Exposure to tobacco smoke at home	ukb-b-4462	0.2103	0.04221	2.15e-06
Qualifications: CSEs or equivalent	ukb-b-10505	0.2067	0.03774	1.79e-07
Mineral and other dietary supplements: Glucosamine	ukb-b-11535	0.2055	0.03419	9.13e-09
Tinnitus, Yes, but not now, but have in the past	ukb-d-4803_14	0.2052	0.06871	0.005
Number of cigarettes previously smoked daily	ukb-b-6019	0.2036	0.03921	7.72e-07
Neuroticism score	ukb-b-4630	0.2006	0.03033	2.24e-10
Time spent watching television	ukb-b-5192	0.1964	0.0236	7.45e-16
Trunk fat percentage	ukb-b-16407	0.196	0.02144	6.49e-19
Handedness (chirality/laterality): Use both right and left hands equally	ukb-a-37	0.1957	0.09527	0.063
Frequency of heavy DIY in last 4 weeks	ukb-b-5053	0.1954	0.05564	0.001
Fractured bone site(s): Spine	ukb-b-873	0.1952	0.1851	0.361
Diagnoses - main ICD-10: N40 Hyperplasia of prostate	ukb-b-11601	0.1951	0.06251	0.004
Duration of heavy DIY	ukb-b-2634	0.1947	0.04471	3.90e-05
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Blood pressure medication	ukb-b-18009	0.1943	0.028	2.51e-11
Diagnoses - main ICD-10: K60 Fissure and fistula of anal and rectal regions	ukb-a-556	0.1928	0.08046	0.028
Light smokers, at least 100 smokes in lifetime	ukb-b-8133	0.1926	0.03768	1.16e-06
Neuroticism	ebi-a-GCST005232	0.1912	0.03064	2.36e-09
Job involves mainly walking or standing	ukb-b-4461	0.1886	0.02835	1.77e-10

Eye problems/disorders: Injury or trauma resulting in loss of vision	ukb-b-9050	0.1877	0.1193	0.163
Diagnoses - main ICD-10: N81 Female genital prolapse	ukb-a-577	0.1876	0.06647	0.009
HOMA-IR	ieu-b-118	0.1872	0.07464	0.021
Eye problems/disorders: Diabetes related eye disease	ukb-b-10181	0.1868	0.06675	0.010
Ever manic/hyper for 2 days	ukb-b-15272	0.1843	0.05674	0.002
Tense/'highly strung'	ukb-b-10093	0.1842	0.0309	1.21e-08
Cataract	bbj-a-94	0.1822	0.08889	0.063
Illness, injury, bereavement, stress in the last 2 years: Marital separation/divorce	ukb-b-14624	0.181	0.0859	0.056
Vitamin and mineral supplements: Vitamin E	ukb-b-12506	0.1799	0.06726	0.014
Fractured bone site(s): Other bones	ukb-b-17738	0.1795	0.05673	0.003
Diagnoses - main ICD-10: S76 Injury of muscle and tendon at hip and thigh level	ukb-a-592	0.1791	0.1568	0.321
Fractured bone site(s): Ankle	ukb-b-15582	0.1766	0.07074	0.022
Triglycerides	ieu-b-111	0.1758	0.02727	6.61e-10
Hearing difficulty/problems: Yes	ukb-a-257	0.1754	0.03368	7.23e-07
Diagnoses - main ICD-10: K80 Cholelithiasis	ukb-a-559	0.171	0.06786	0.020
Smoking status: Previous	ukb-a-224	0.1702	0.03021	7.61e-08
Diagnoses - main ICD-10: K57 Diverticular disease of intestine	ukb-a-555	0.17	0.05136	0.002
Headache	ukb-b-12181	0.1688	0.03406	2.45e-06
Diagnoses - main ICD-10: K76 Other diseases of liver	ukb-a-558	0.168	0.09632	0.118
Irritability	ukb-b-13745	0.1665	0.03492	6.00e-06
Alcohol intake versus 10 years previously	ukb-b-3460	0.1647	0.032	9.70e-07
Number of full sisters	ukb-b-5593	0.1629	0.04458	0.0006
Duration of moderate activity	ukb-b-2346	0.1609	0.03531	1.60e-05
Illness, injury, bereavement, stress in the last 2 years: Death of a close relative	ukb-b-18712	0.1581	0.05821	0.012
Types of transport used (excluding work): None of the above	ukb-b-12386	0.1556	0.1264	0.286
Prospective memory result	ukb-b-4282	0.1544	0.03804	0.0001
Tinnitus, Yes, now a lot of the time	ukb-d-4803_12	0.154	0.1353	0.322
Risk taking	ukb-b-14147	0.1538	0.0283	2.21e-07
Diagnoses - main ICD-10: I30 Acute pericarditis	ukb-a-535	0.1515	0.1111	0.233
Pulse wave reflection index	ukb-b-11598	0.1515	0.04294	0.0009
Ever smoked	ukb-b-20261	0.1515	0.02426	2.32e-09
Diagnoses - main ICD-10: J33 Nasal polyp	ukb-a-541	0.1493	0.1045	0.211
Exposure to tobacco smoke outside home	ukb-b-6244	0.1492	0.03656	0.0001
Ever depressed for a whole week	ukb-b-6848	0.1484	0.04074	0.0006
Cough on most days	ukb-b-16858	0.1483	0.05386	0.011
Diagnoses - main ICD-10: R55 Syncope and collapse	ukb-b-16187	0.148	0.0645	0.036
Time spent driving	ukb-b-3793	0.1459	0.03543	0.0001
Suffer from 'nerves'	ukb-b-19957	0.1453	0.03408	5.66e-05
Length of working week for main job	ukb-b-8013	0.1435	0.04645	0.004
Duration of vigorous activity	ukb-b-13932	0.1426	0.0408	0.001
Alcohol intake frequency	ukb-b-5779	0.1426	0.02293	2.62e-09
Number of live births	ukb-b-1209	0.1425	0.02977	5.50e-06
Frequency of walking for pleasure in last 4 weeks	ukb-b-4655	0.1412	0.03298	5.30e-05
Diagnoses - main ICD-10: M10 Gout	ukb-a-561	0.1407	0.111	0.272
Fractured/broken bones in the last 5 years	ukb-b-13346	0.138	0.03926	0.001
Comparative body size at age 10	ukb-b-4650	0.1374	0.02317	1.43e-08
Sensitivity/hurt feelings	ukb-b-9981	0.1371	0.02911	7.85e-06
Hearing difficulty/problems with background noise	ukb-b-18275	0.1368	0.0274	2.04e-06
Duration of walks	ukb-b-16998	0.1361	0.02992	1.65e-05
Vitamin and mineral supplements: Folic acid or Folate (Vitamin B9)	ukb-b-3563	0.1344	0.09683	0.224
HOMA-B	ieu-b-117	0.1339	0.06558	0.064
Ischemic stroke	ebi-a-GCST005843	0.1334	0.04006	0.002
Tinnitus, Yes, now some of the time	ukb-d-4803_13	0.1334	0.08961	0.190
Hearing aid user	ukb-b-19060	0.1302	0.04883	0.014
Ever had prostate specific antigen (PSA) test	ukb-b-15695	0.128	0.0387	0.002
Average weekly intake of other alcoholic drinks	ukb-b-3831	0.1275	0.2105	0.612
Diagnoses - main ICD-10: S66 Injury of muscle and tendon at wrist and hand level	ukb-a-591	0.1273	0.09657	0.252
Duration of light DIY	ukb-b-2993	0.1268	0.03888	0.002
Sodium in urine	ukb-a-335	0.1252	0.02768	1.86e-05
Mouth/teeth dental problems: Loose teeth	ukb-b-12849	0.1243	0.04745	0.016
Townsend deprivation index at recruitment	ukb-b-10011	0.1235	0.03261	0.0004
Squamous cell lung cancer	ieu-a-967	0.1202	0.1038	0.314
Weight change compared with 1 year ago	ukb-b-2094	0.1202	0.04725	0.019
Diagnoses - main ICD-10: N32 Other disorders of bladder	ukb-a-575	0.1198	0.08434	0.213
Fractured bone site(s): Leg	ukb-b-3798	0.1194	0.1347	0.448
Creatinine (enzymatic) in the urine	ukb-a-333	0.1178	0.02655	2.72e-05
Chronic kidney disease	ieu-a-1102	0.1174	0.07639	0.175
Diagnoses - main ICD-10: I80 Phlebitis and thrombophlebitis	ukb-a-537	0.1137	0.06562	0.121

Number of children ever born measurement	ieu-b-4828	0.1126	0.06696	0.134
Used an inhaler for chest within last hour	ukb-b-11188	0.1112	0.09264	0.298
Forearm bone mineral density	ieu-a-977	0.1098	0.1023	0.352
Illness, injury, bereavement, stress in the last 2 years: Serious illness, injury, or assault of a close relative	ukb-b-9049	0.108	0.05784	0.093
Daytime dozing/sleeping (narcolepsy)	ukb-b-5776	0.1071	0.02811	0.0003
Tinnitus, Yes, now most or all the time	ukb-d-4803_11	0.1071	0.05537	0.081
Heel bone mineral density (BMD) T-score, automated	ukb-b-20124	0.104	0.02594	0.0002
Doctor diagnosed hayfever or allergic rhinitis	ukb-b-7178	0.1033	0.03617	0.008
Guilty feelings	ukb-b-10169	0.1031	0.03145	0.002
Why reduced smoking: None of the above	ukb-b-19752	0.1028	0.2225	0.700
Mineral and other dietary supplements: Fish oil (including cod liver oil)	ukb-b-11075	0.1024	0.0325	0.003
Types of transport used (excluding work): Car/motor vehicle	ukb-b-16886	0.1007	0.03278	0.004
Lung adenocarcinoma	ieu-a-965	0.1002	0.1299	0.512
Diagnoses - main ICD-10: S09 Other and unspecified injuries of head	ukb-a-589	0.09838	0.08634	0.322
Ever taken oral contraceptive pill	ukb-b-9509	0.09814	0.04513	0.049
Cancer diagnosed by doctor	ukb-b-16855	0.09713	0.05768	0.133
Worrier/anxious feelings	ukb-b-6519	0.09618	0.0298	0.003
Headaches for 3+ months	ukb-b-13092	0.09525	0.04212	0.039
Non-accidental death in close genetic family	ukb-b-19722	0.09376	0.06716	0.222
Diastolic blood pressure, automated reading	ukb-b-7992	0.09332	0.02266	0.0001
Mineral and other dietary supplements: Zinc	ukb-b-13891	0.09248	0.04737	0.078
Duration of strenuous sports	ukb-b-1046	0.08947	0.08951	0.390
Vitamin and mineral supplements: Multivitamins +/- minerals	ukb-b-16812	0.08725	0.03723	0.032
Frequency of travelling from home to workplace	ukb-b-185	0.08528	0.04487	0.087
Number of cigarettes currently smoked daily (current cigarette smokers)	ukb-b-469	0.08419	0.05766	0.199
Sitting height ratio	ieu-a-1070	0.0792	0.04958	0.156
Diagnoses - main ICD-10: E04 Other non-toxic goitre	ukb-a-524	0.07919	0.07815	0.382
Comparative height size at age 10	ukb-a-35	0.07918	0.02399	0.002
Femoral neck bone mineral density	ieu-a-980	0.07917	0.04109	0.083
Systemic lupus erythematosus	ebi-a-GCST003156	0.07866	0.05133	0.176
Diagnoses - main ICD-10: I48 Atrial fibrillation and flutter	ukb-b-964	0.07756	0.04915	0.161
Diagnoses - main ICD-10: L03 Cellulitis	ukb-a-560	0.07584	0.09574	0.499
Sitting height	ukb-b-16881	0.07438	0.02223	0.002
Reason for reducing amount of alcohol drunk: Financial reasons	ukb-d-2664_4	0.07341	0.08587	0.464
Nap during day	ukb-b-4616	0.07316	0.02342	0.004
Eye problems/disorders: Cataract	ukb-b-8329	0.07225	0.05873	0.286
Loud music exposure frequency	ukb-b-5436	0.06994	0.0469	0.190
Mineral and other dietary supplements: Selenium	ukb-b-19158	0.06769	0.0702	0.409
Systolic blood pressure, automated reading	ukb-b-20175	0.06732	0.02413	0.010
Duration of other exercises	ukb-b-4512	0.06716	0.0567	0.304
Multiple sclerosis	ieu-b-18	0.06693	0.03586	0.093
Handedness (chirality/laterality): Right-handed	ukb-d-1707_1	0.06594	0.05767	0.321
Extreme height	ieu-a-86	0.06538	0.03967	0.142
Pulse rate, automated reading	ukb-b-18103	0.06127	0.02302	0.014
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Insulin	ukb-b-14070	0.06009	0.08896	0.569
Vitamin and mineral supplements: Vitamin C	ukb-b-15175	0.06003	0.05097	0.307
Had menopause	ukb-b-18105	0.05961	0.04721	0.272
Urinary albumin-to-creatinine ratio	ieu-a-1107	0.05954	0.07012	0.466
Serum creatinine	bbj-a-61	0.05629	0.03415	0.142
Wears glasses or contact lenses	ukb-b-14576	0.05596	0.04624	0.294
Primary biliary cirrhosis	ebi-a-GCST005581	0.05485	0.09256	0.621
Average weekly beer plus cider intake	ukb-b-5174	0.05434	0.03398	0.156
Diagnoses - main ICD-10: H26 Other cataract	ukb-a-530	0.05375	0.06039	0.448
Diagnoses - main ICD-10: N20 Calculus of kidney and ureter	ukb-a-574	0.05303	0.07094	0.525
Diagnoses - main ICD-10: I83 Varicose veins of lower extremities	ukb-a-538	0.05231	0.04598	0.322
Reason for glasses/contact lenses: For a 'lazy' eye or an eye with poor vision since childhood (called 'amblyopia')	ukb-b-9139	0.05117	0.08338	0.607
Circulating leptin levels	ebi-a-GCST003367	0.05094	0.05746	0.448
Type of tobacco previously smoked: Manufactured cigarettes	ukb-d-2877_1	0.0508	0.07762	0.581
Vitamin and mineral supplements: Vitamin D	ukb-b-12648	0.04979	0.06548	0.518
Bipolar disorder	ieu-b-41	0.04951	0.02938	0.133
C-reactive protein	bbj-a-14	0.04877	0.09683	0.674
Distance between home and workplace	ukb-b-20455	0.04753	0.06883	0.560
Platelet count	ukb-d-30080_irt	0.0472	0.02128	0.044
Offspring birth weight	ebi-a-GCST005314	0.04685	0.04316	0.346
Diagnoses - main ICD-10: H26.9 Cataract, unspecified	ukb-b-12397	0.04672	0.05476	0.464
Cerebral aneurysm	bbj-a-96	0.04643	0.05856	0.499
Difference in height between childhood and adulthood	ieu-a-1037	0.04638	0.06269	0.529

HbA1c	ieu-b-4842	0.04572	0.04479	0.378
Mouth/teeth dental problems: Mouth ulcers	ukb-b-6458	0.04534	0.03238	0.220
Main ICD-10: D12 Benign neoplasm of colon, rectum, anus, and anal canal	ukb-d-D12	0.04429	0.05291	0.473
Number of unsuccessful stop-smoking attempts	ukb-b-4801	0.04343	0.04976	0.456
Diagnoses - main ICD-10: H25 Senile cataract	ukb-a-529	0.04242	0.1048	0.731
Diagnoses - main ICD-10: K50 Crohn's disease [regional enteritis]	ukb-a-552	0.04179	0.08783	0.693
Platelet crit	ukb-d-30090 irmt	0.04057	0.02228	0.101
Family relationship satisfaction	ukb-b-3666	0.04006	0.03337	0.297
Diagnoses - main ICD-10: D25 Leiomyoma of uterus	ukb-a-522	0.03965	0.06031	0.579
Forced expiratory volume in 1-second (FEV1) , predicted	ukb-b-8428	0.03778	0.03093	0.289
Nervous feelings	ukb-b-20544	0.0364	0.03145	0.314
Number of days/week of moderate physical activity 10+ minutes	ukb-b-4710	0.03618	0.03084	0.308
Number of incorrect matches in round	ukb-b-20498	0.03595	0.02599	0.226
Diagnoses - main ICD-10: C61 Malignant neoplasm of prostate	ukb-b-2160	0.03195	0.076	0.722
Work/job satisfaction	ukb-b-2105	0.03118	0.04671	0.574
Inflammatory bowel disease	ebi-a-GCST004131	0.03061	0.03342	0.436
Lung function (FEV1/FVC)	ebi-a-GCST007431	0.02682	0.02254	0.302
Transferrin	ieu-a-1052	0.02659	0.07843	0.781
Alcohol drinker status: Never	ukb-a-226	0.02626	0.04579	0.631
Ferritin levels	ebi-a-GCST005072	0.02617	0.06198	0.722
Number of pregnancy terminations	ukb-b-4958	0.02551	0.04773	0.657
Systolic blood pressure	ieu-b-38	0.02419	0.02088	0.314
Frequency of other exercises in last 4 weeks	ukb-b-3502	0.02272	0.0467	0.687
Reason for glasses/contact lenses: For a 'squint' or 'turn' in an eye since childhood (called 'strabismus')	ukb-b-11465	0.02246	0.07296	0.799
Uric acid	bbj-a-57	0.0221	0.02761	0.496
Potassium in urine	ukb-a-334	0.02044	0.03224	0.594
Fractured bone site(s): Wrist	ukb-b-9571	0.0188	0.06779	0.817
Diastolic blood pressure	ieu-b-39	0.01799	0.02164	0.477
Number of days/weeks of vigorous physical activity 10+ minutes	ukb-b-151	0.01773	0.02777	0.592
Hand grip strength	ukb-b-7478	0.01671	0.02272	0.531
Standing height	ukb-b-10787	0.01637	0.02086	0.503
Happiness	ukb-b-4062	0.01437	0.03424	0.722
Diagnoses - main ICD-10: K51 Ulcerative colitis	ukb-a-553	0.01424	0.07698	0.877
Reason for glasses/contact lenses: For long-sightedness (called 'hypermetropia')	ukb-b-18189	0.01392	0.06018	0.849
Eczema	ieu-a-996	0.01207	0.06553	0.877
Type of tobacco previously smoked: Hand-rolled cigarettes	ukb-d-2877_2	0.01138	0.1056	0.926
Diagnoses - main ICD-10: K40 Inguinal hernia	ukb-a-549	0.01124	0.05112	0.854
Reason for reducing amount of alcohol drunk: Other reason	ukb-d-2664_5	0.009846	0.04397	0.852
Diagnoses - main ICD-10: M72 Fibroblastic disorders	ukb-a-572	0.007981	0.05224	0.894
Underlying (primary) cause of death: ICD-10 C34.9 Bronchus or lung, unspecified	ukb-d-40001_C349	0.007745	0.1028	0.950
Worry too long after embarrassment	ukb-b-13653	0.007505	0.0289	0.829
Total cholesterol	ieu-a-301	0.006143	0.03893	0.893
Diagnoses - main ICD-10: Z47 Other orthopaedic follow-up care	ukb-a-595	0.005589	0.08483	0.952
Peak expiratory flow (PEF)	ukb-b-12019	0.005417	0.02583	0.860
Apolipoprotein B	ieu-b-108	0.004527	0.02631	0.885
Hand grip strength (right)	ukb-b-10215	0.004473	0.02308	0.871
Amyotrophic lateral sclerosis	ebi-a-GCST005647	0.002829	0.06731	0.969
Frequency of light DIY in last 4 weeks	ukb-b-4210	0.002088	0.04373	0.966
Difference in height between adolescence and adulthood	ieu-a-1040	0.001982	0.06836	0.978
Number of depression episodes	ukb-b-1464	-0.00611	0.08342	0.950
Platelet distribution width	ukb-d-30110 irmt	-0.00867	0.02691	0.792
Alzheimer's disease	ieu-b-2	-0.01049	0.06436	0.891
Birth weight	ukb-b-13378	-0.01258	0.02386	0.659
Mineral and other dietary supplements: Calcium	ukb-b-7043	-0.0161	0.0504	0.792
Diagnoses - main ICD-10: E03 Other hyperthyroidism	ukb-a-523	-0.01671	0.2381	0.950
Diagnoses - main ICD-10: C50 Malignant neoplasm of breast	ukb-a-519	-0.01701	0.05611	0.801
Reproducibility of spirometry measurement using ERS/ATS criteria	ukb-b-19066	-0.01711	0.05166	0.786
Friendship satisfaction	ukb-b-3304	-0.01741	0.03693	0.694
Mean platelet volume	ebi-a-GCST004599	-0.01764	0.02027	0.456
Number of days/week walked 10+ minutes	ukb-b-4886	-0.01806	0.03092	0.624
Glaucoma	bbj-a-121	-0.01828	0.06901	0.826
Schizophrenia	ieu-a-22	-0.02027	0.02541	0.497
Diagnoses - main ICD-10: F43 Reaction to severe stress and adjustments disorders	ukb-a-526	-0.02277	0.201	0.923
Birth weight of first child	ukb-b-3357	-0.02364	0.02856	0.478
Diagnoses - main ICD-10: N19 Unspecified renal failure	ukb-a-573	-0.02447	0.1021	0.843
Diagnoses -main ICD-10: C44 Other malignant neoplasm of skin	ukb-a-518	-0.02504	0.05774	0.717
Mean platelet (thrombocyte) volume	ukb-d-30100 irmt	-0.02601	0.01979	0.253

Infant head circumference	ieu-a-28	-0.02848	0.06305	0.706
Pallidum volume	ieu-a-1046	-0.02874	0.06629	0.717
Ferritin	ieu-a-1050	-0.02992	0.08485	0.772
Forced expiratory volume 1-second (FEV1), Best measure	ukb-b-11141	-0.03696	0.02462	0.186
Time spent using computer	ukb-b-4522	-0.04105	0.02322	0.113
Forced expiratory volume in 1-second (FEV1)	ukb-b-19657	-0.0428	0.02356	0.102
Getting up in the morning	ukb-b-2772	-0.04464	0.02434	0.099
Neo-conscientiousness	ieu-a-114	-0.04494	0.1065	0.722
Mouth/teeth dental problems: Bleeding gums	ukb-b-7872	-0.04589	0.0336	0.232
Type of tobacco previously smoked: Cigars and pipes	ukb-a-327	-0.0459	0.09557	0.690
Forced vital capacity (FVC), Best measure	ukb-b-14713	-0.04689	0.02442	0.084
LDL cholesterol	ieu-b-110	-0.04904	0.02707	0.103
Nucleus accumbens volume	ieu-a-1042	-0.04971	0.1114	0.709
Forced vital capacity (FVC)	ukb-b-7953	-0.05151	0.02353	0.047
Mineral and other dietary supplements: Iron	ukb-b-14863	-0.05167	0.06936	0.526
Autism spectrum disorder	ieu-a-1185	-0.05266	0.04111	0.266
Fractured bone site(s): Arm	ukb-b-19255	-0.05672	0.105	0.654
Morning/evening person (chronotype)	ukb-b-4956	-0.05691	0.02258	0.020
Diagnoses - main ICD-10: K35 Acute appendicitis	ukb-a-548	-0.05788	0.1269	0.703
Subjective well being	ieu-a-1009	-0.06181	0.04731	0.256
Forced expiratory volume 1-second (FEV1), predicted percentage	ukb-b-13405	-0.06315	0.02909	0.049
Putamen volume	ieu-a-1047	-0.06383	0.05789	0.338
Parkinson's disease	ieu-b-7	-0.06416	0.04234	0.182
Thalamus volume	ieu-a-1048	-0.06972	0.07702	0.441
Anorexia nervosa	ieu-a-1186	-0.07211	0.05064	0.212
Caudate volume	ieu-a-1044	-0.07359	0.0623	0.306
Reason for glasses/contact lenses: For just reading/near work as you are getting old (called 'presbyopia')	ukb-b-16235	-0.07856	0.09162	0.463
Age at menarche	ieu-b-4822	-0.08198	0.04917	0.137
Mean time to correctly identify matches	ukb-b-16287	-0.08454	0.02531	0.002
Fracture resulting from simple fall	ukb-b-15251	-0.08524	0.06992	0.290
Length of menstrual cycle	ukb-b-3278	-0.09299	0.04312	0.050
Diagnoses - main ICD-10: O75 Other complications of labour and delivery not elsewhere classified	ukb-a-579	-0.09448	0.09706	0.405
Vitamin and mineral supplements: None of the above	ukb-b-17381	-0.09521	0.03501	0.012
Relative age of first facial hair	ukb-b-5945	-0.09538	0.02687	0.0009
Fasting blood glucose adjusted for BMI	ebi-a-GCST007858	-0.09635	0.1085	0.448
Mineral and other dietary supplements: None of the above	ukb-b-14238	-0.1002	0.03205	0.004
Diagnoses - main ICD-10: Z80 Family history of malignant neoplasm	ukb-a-596	-0.1051	0.1798	0.624
Celiac disease	ebi-a-GCST000612	-0.111	0.06049	0.099
Adiponectin	ieu-a-1	-0.1113	0.09904	0.328
Handedness (chirality/laterality): Left-handed	ukb-a-36	-0.1159	0.05793	0.071
Primary sclerosing cholangitis	ieu-a-1112	-0.116	0.06281	0.097
Underlying (primary) cause of death: ICD-10 E85.4 Organ limited amyloidosis	ukb-a-357	-0.1165	0.1516	0.513
Reason for glasses/contact lenses: For 'astigmatism'	ukb-b-10937	-0.1169	0.05444	0.051
Hippocampus volume	ieu-a-1045	-0.1174	0.07937	0.194
Circulating leptin levels adjusted for BMI	ebi-a-GCST003368	-0.1182	0.06261	0.089
Types of physical activity in the last 4 weeks: Heavy DIY	ukb-b-13184	-0.1209	0.03288	0.0005
ICD-10:H40 Glaucoma	ukb-d-H40	-0.1261	0.09974	0.272
Average weekly red wine intake	ukb-b-5239	-0.1266	0.03039	8.55e-05
Snoring	ukb-b-17400	-0.1289	0.02703	6.01e-06
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: Oral contraceptive pill or minipill	ukb-b-9547	-0.1313	0.09084	0.204
Target heart rate achieved	ukb-b-16609	-0.1325	0.06173	0.051
Time from waking to first cigarette	ukb-b-2732	-0.1334	0.05758	0.034
Average weekly champagne plus white wine intake	ukb-b-5716	-0.1334	0.03629	0.0006
Smoking cessation	bbj-a-81	-0.1379	0.05149	0.013
Apolipoprotein A-I	ieu-b-107	-0.1414	0.02614	2.50e-07
Father still alive	ukb-b-13160	-0.1431	0.05824	0.024
Breastfed as a baby	ukb-b-13423	-0.1435	0.03765	0.0003
Age at menarche	ieu-a-1095	-0.1444	0.02859	1.58e-06
Childhood intelligence	ieu-a-16	-0.1468	0.06337	0.034
Types of physical activity in the last 4 weeks: Other exercises	ukb-b-8764	-0.1468	0.02738	3.20e-07
Serum cystatin C (eGFRcys)	ieu-a-1106	-0.1475	0.06321	0.033
Reason for glasses/contact lenses: For short-sightedness (called 'myopia')	ukb-b-6353	-0.1485	0.03691	0.0001
Frequency of stair climbing in the last 4 weeks	ukb-b-298	-0.149	0.03157	7.49e-06
Types of physical activity in the last 4 weeks: Light DIY	ukb-b-11495	-0.1502	0.03017	2.19e-06
Relative age voice broke	ukb-b-5262	-0.1512	0.03396	2.55e-05
Neo-openness to experience	ieu-a-117	-0.1525	0.07922	0.083
Diagnoses - main ICD-10: F31 Bipolar affective disorder	ukb-a-525	-0.1526	0.09155	0.137

Diagnoses - main ICD-10: S52 Fracture of forearm	ukb-a-590	-0.1568	0.07432	0.056
Mouth/teeth dental problems: None of the above	ukb-b-17601	-0.1584	0.03055	7.99e-07
Average weekly fortified wine intake	ukb-b-1070	-0.1603	0.05517	0.007
Types of transport used (excluding work): Public transport	ukb-b-15957	-0.1625	0.03697	3.25e-05
Lung cancer	bbj-a-133	-0.1646	0.1237	0.247
ECG, heart rate	ukb-b-11361	-0.1655	0.0449	0.0005
Age at menopause (last menstrual period)	ukb-b-17422	-0.1659	0.02728	5.94e-09
Fluid intelligence score	ukb-b-5238	-0.166	0.02631	1.53e-09
Sleep duration	ukb-b-4424	-0.1675	0.02803	1.11e-08
Types of physical activity in last 4 weeks: Walking for pleasure	ukb-b-7337	-0.1689	0.03378	1.99e-06
Types of physical activity in last 4 weeks: Strenuous sports	ukb-b-7663	-0.1703	0.03473	3.13e-06
Intelligence	ebi-a-GCST006250	-0.1713	0.02216	8.32e-14
Tinnitus, No, never	ukb-d-4803_0	-0.1768	0.04258	9.05e-05
Types of transport used (excluding work): Cycle	ukb-b-17557	-0.1785	0.03327	3.18e-07
HDL cholesterol	ieu-b-109	-0.1824	0.02405	2.46e-13
Alcohol usually taken with meals	ukb-b-16878	-0.1868	0.02924	9.45e-10
Impedance of leg (left)	ukb-b-14068	-0.1874	0.02057	8.50e-19
Qualifications: Other professional qualifications e.g., nursing, teaching	ukb-b-13799	-0.1893	0.03094	4.77e-09
Impedance of leg (right)	ukb-b-7376	-0.1926	0.01997	6.12e-21
Duration walking for pleasure	ukb-b-703	-0.198	0.03999	2.49e-06
Types of transport used (excluding work): Walk	ukb-b-14926	-0.1986	0.03351	1.46e-08
Past tobacco smoking	ukb-b-2134	-0.2033	0.0239	1.639e-16
Reason for glasses/contact lenses: Other eye condition	ukb-b-15297	-0.209	0.1863	0.329
Transport type for commuting to workplace: Walk	ukb-b-15005	-0.2099	0.05665	0.0005
Former vs current smoker	ieu-a-963	-0.2132	0.06222	0.001
Underlying (primary) cause of death: ICD-10 J84.1 Other interstitial pulmonary diseases with fibrosis	ukb-a-358	-0.222	0.151	0.196
Maximum workload during fitness test	ukb-b-7551	-0.222	0.05436	0.0001
Alcohol drinker status: Current	ukb-d-20117_2	-0.2226	0.04012	1.21e-07
Started insulin within one year diagnosis of diabetes	ukb-b-8388	-0.2308	0.0789	0.007
Transport type for commuting to workplace: Cycle	ukb-b-15787	-0.2329	0.03618	6.97e-10
Transport type for commuting to workplace: Public transport	ukb-b-17155	-0.2347	0.03922	1.07e-08
Smoking status: Never	ukb-d-20116_0	-0.2386	0.02478	7.13e-21
Qualifications: O levels/GCSEs or equivalent	ukb-b-18099	-0.2447	0.02971	1.46e-15
Vascular/heart problems diagnosed by doctor: None of the above	ukb-b-13352	-0.2457	0.02317	4.30e-25
Pulse wave peak to peak time	ukb-b-8778	-0.2469	0.04531	2.05e-07
Impedance of whole body	ukb-b-19921	-0.2556	0.02064	7.70e-34
Why reduced smoking: Health precaution	ukb-b-13026	-0.2562	0.1216	0.056
Age of smoking initiation	ieu-b-24	-0.259	0.03105	6.37e-16
Years of schooling	ieu-a-1239	-0.2629	0.01929	1.39e-40
College completion	ieu-a-836	-0.2667	0.04041	2.45e-10
Qualifications: College or University degree	ukb-b-16489	-0.2679	0.02191	5.28e-33
Mother's age at death	ukb-b-12687	-0.2702	0.04147	4.25e-10
Illness, injury, bereavement, stress in the last 2 years: None of the above	ukb-b-17687	-0.2722	0.03142	4.36e-17
Age completed full time education	ukb-b-6134	-0.2722	0.02826	7.04e-21
Maximum heart rate during fitness test	ukb-b-14461	-0.2746	0.05061	2.33e-07
Qualifications: A levels/ AS levels or equivalent	ukb-b-11615	-0.2759	0.02525	1.35e-26
Father's age at death	ukb-b-11303	-0.2784	0.03921	8.12e-12
Impedance of arm (right)	ukb-b-7859	-0.2824	0.02113	3.82e-39
Usual walking pace	ukb-b-4711	-0.2833	0.02477	5.32e-29
Impedance of arm (left)	ukb-b-19379	-0.2844	0.02141	1.03e-38
Parental longevity	ebi-a-GCST006702	-0.2877	0.03995	4.02e-12
Medication for cholesterol, blood pressure, diabetes or take exogenous hormones: None of the above	ukb-b-20379	-0.2901	0.03107	1.09e-19
Duration of fitness test	ukb-b-6011	-0.301	0.09015	0.002
Age started oral contraceptive pill	ukb-b-9433	-0.3324	0.03679	1.65e-18
Age at first live birth	ukb-b-12405	-0.3432	0.02573	5.27e-39
Age at last live birth	ukb-b-8727	-0.3554	0.03246	1.08e-26
Medication for pain relief, constipation, heartburn: No medication	ukb-b-11085	-0.4178	0.02462	2.02e-62
Pain types experienced in last month: None of the above	ukb-b-9130	-0.5107	0.02724	7.48e-76

Table S10. Exposures potentially causal for LSS, and outcomes that LSS was potentially found to be causal for. Mendelian randomization was performed by using TwoSampleMR-database and the phenotype IDs used in the analysis were extracted from the MRC-IEU database. For the analysis, we extracted genetic instruments from FinnGen+EstBB based meta-analysis results. Inverse variance weighted-model was used as a main method, but MR Egger was also utilised as a sensitivity analysis. $P < 0.05$ was used as a threshold for statistical significance. nsnp, number of SNPs; OR, odds ratio, pFDR, false discovery rate-corrected p-value; pHET, p-value for heterogeneity; pPLE, p-value for pleiotropy

Direction	Trait	Method	nsnp	Causal estimate scale	Causal estimate	pFDR	pHET	Egger intercept	pPLE
Trait-> SS	Whole body fat-free mass id:ukb-b-13354	IVW	481	OR	1.78 (1.59–1.99)	2.22e-21	1.53e-46		
	Whole body fat-free mass id:ukb-b-13354	MR Egger	481	OR	1.53 (1.17–2.00)	0.004	2.53e-46	0.0023	0.2255
Trait-> SS	Hip circumference id:ukb-b-15590	IVW	369	OR	1.51 (1.38–1.64)	2.62e-18	1.05e-26		
	Hip circumference id:ukb-b-15590	MR Egger	369	OR	1.60 (1.26–2.03)	0.0004	8.49e-27	-0.0012	0.6042
Trait-> SS	Whole body fat mass id:ukb-b-19393	IVW	383	OR	1.48 (1.35–1.63)	2.82e-15	3.46e-35		
	Whole body fat mass id:ukb-b-19393	MR Egger	383	OR	1.66 (1.28–2.16)	0.0004	3.86e-35	-0.0022	0.3585
Trait-> SS	Body mass index (BMI) id:ukb-b-19953	IVW	387	OR	1.55 (1.42–1.70)	2.22e-21	8.53e-26		
	Body mass index (BMI) id:ukb-b-19953	MR Egger	387	OR	1.60 (1.26–2.03)	0.0004	6.31e-26	-0.0006	0.7846
SS-> Trait	Back pain id:ukb-b-983	IVW	33	Beta	0.02 (0.01-0.03)	0.0001	2.46e-14		
	Back pain id:ukb-b-983	MR Egger	33	Beta	0.03 (-0.02-0.07)	0.581	1.18e-14	-0.00017	0.9247

Table S11. Risk factors that were extracted from the GWAS database provided by the MRC Integrative Epidemiology Unit (IEU) (<https://gwas.mrcieu.ac.uk/>) and were used in the bi-directional mendelian randomization.

GWAS-ID	Year	Trait	Consortium	Sample size	Number of SNP's
ieu-b-35	2018	C-reactive protein level	NA	204402	2414379
met-d-GlycA	2020	Glycoprotein acetyls	NA	115078	12321875
ukb-b-13354	2018	Whole body fat-free mass	MRC-IEU	454850	9851867
ukb-b-15590	2018	Hip circumference	MRC-IEU	462117	9851867
ukb-b-19393	2018	Whole body fat mass	MRC-IEU	454137	9851867
ukb-b-19953	2018	Body mass index (BMI)	MRC-IEU	461460	9851867
ukb-b-3957	2018	Sleeplessness/insomnia	MRC-IEU	462341	9851867
ukb-b-929	2018	Frequency of tiredness/lethargy in last 2 weeks	MRC-IEU	449019	9851867
ukb-b-9838	2018	Back pain	MRC-IEU	461857	9851867

References

1. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput Biol* **11**, e1004219 (2015).
2. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
3. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* **53**, 1415–1424 (2021).
4. Suri, P. *et al.* Genome-wide association studies of low back pain and lumbar spinal disorders using electronic health record data identify a locus associated with lumbar spinal stenosis. *Pain* **162**, 2263–2272 (2021).
5. Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank. *Nucleic Acids Res* **44**, D67–D72 (2016).
6. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* **47**, D506–D515 (2019).
7. Stanfill, A. G. & Cao, X. Enhancing Research Through the Use of the Genotype-Tissue Expression (GTEx) Database. *Biol Res Nurs* **23**, 533–540 (2021).
8. Cortes, A. *et al.* Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* **45**, 730–738 (2013).
9. Abe, Y. *et al.* Proinflammatory Cytokines Stimulate the Expression of Nerve Growth Factor by Human Intervertebral Disc Cells. *SPINE* vol. 32.
10. Freemont, A. J. *et al.* Nerve growth factor expression and innervation of the painful intervertebral disc. *Journal of Pathology* **197**, 286–292 (2002).
11. Hu, H. *et al.* OTUD7B controls non-canonical NF- κ B activation through deubiquitination of TRAF3. *Nature* **494**, 371–374 (2013).
12. Zhang, H., Liu, D. & Fan, X. Diagnostic and prognostic significance of miR-486-5p in patients who underwent minimally invasive surgery for lumbar spinal stenosis. *European Spine Journal* **33**, 1979–1985 (2024).
13. Russo, S. *et al.* A mutation in the ZNF687 gene that is responsible for the severe form of Paget’s disease of bone causes severely altered bone remodeling and promotes hepatocellular carcinoma onset in a knock-in mouse model. *Bone Res* **11**, 16 (2023).
14. Divisato, G. *et al.* ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. *Am J Hum Genet* **98**, 275–86 (2016).
15. Varela, D., Varela, T., Conceição, N. & Cancela, M. L. Regulation of human ZNF687, a gene associated with Paget’s disease of bone. *Int J Biochem Cell Biol* **154**, 106332 (2023).
16. Jacobsen, M. *et al.* A point mutation in PTPRC is associated with the development of multiple sclerosis. *Nat Genet* **26**, 495–499 (2000).
17. Dunlock, V.-M. E. *et al.* Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. *Cell Rep* **39**, 111006 (2022).
18. Luo, W., Zhang, G., Wang, Z., Wu, Y. & Xiong, Y. Ubiquitin-specific proteases: Vital regulatory molecules in bone and bone-related diseases. *Int Immunopharmacol* **118**, 110075 (2023).
19. Sun, C., Ma, Q., Yin, J., Zhang, H. & Liu, X. WISP-1 induced by mechanical stress contributes to fibrosis and hypertrophy of the ligamentum flavum through Hedgehog-Gli1 signaling. *Exp Mol Med* **53**, 1068–1079 (2021).
20. Qin, T. *et al.* Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. *J Exp Clin Cancer Res* **37**, 287 (2018).

21. Wright, K. M. *et al.* Dystroglycan organizes axon guidance cue localization and axonal pathfinding. *Neuron* **76**, 931–44 (2012).
22. Jahncke, J. N. & Wright, K. M. The many roles of dystroglycan in nervous system development and function. *Developmental Dynamics* **252**, 61–80 (2023).
23. Dai, Y. *et al.* Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. *J Cell Mol Med* **23**, 811–818 (2019).
24. Wang, F. M. *et al.* Aging of the Spine: Characterizing genetic and physiological determinants of spinal curvature. doi:10.1101/2024.02.27.24303450.
25. Veleri, S., Punnakkal, P., Dunbar, G. L. & Maiti, P. Molecular Insights into the Roles of Rab Proteins in Intracellular Dynamics and Neurodegenerative Diseases. *Neuromolecular Med* **20**, 18–36 (2018).
26. Jiang, J. *et al.* Involvement of Rab28 in NF- κ B Nuclear Transport in Endothelial Cells. *PLoS One* **8**, (2013).
27. Prunier, C. & Howe, P. H. Disabled-2 (Dab2) Is Required for Transforming Growth Factor β -induced Epithelial to Mesenchymal Transition (EMT). *Journal of Biological Chemistry* **280**, 17540–17548 (2005).
28. Figliuolo da Paz, V., Ghishan, F. K. & Kiela, P. R. Emerging Roles of Disabled Homolog 2 (DAB2) in Immune Regulation. *Frontiers in Immunology* vol. 11 Preprint at <https://doi.org/10.3389/fimmu.2020.580302> (2020).
29. Wang, D. *et al.* Cyclic Mechanical Stretch Ameliorates the Degeneration of Nucleus Pulposus Cells through Promoting the ITGA2/PI3K/AKT Signaling Pathway. *Oxid Med Cell Longev* **2021**, 1–11 (2021).
30. Nechanitzky, R. *et al.* Transcription factor EBF1 is essential for the maintenance of B cell identity and prevention of alternative fates in committed cells. *Nat Immunol* **14**, 867–875 (2013).
31. Yang, C.-Y. *et al.* Interaction of CCR4-NOT with EBF1 regulates gene-specific transcription and mRNA stability in B lymphopoiesis. *Genes Dev* **30**, 2310–2324 (2016).
32. Kugimiya, F. *et al.* Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. *Journal of Biological Chemistry* **280**, 35704–35712 (2005).
33. Ebisawa, T. *et al.* Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. *J Cell Sci* **112** (Pt 20), 3519–27 (1999).
34. Crews, L. *et al.* Increased BMP6 levels in the brains of Alzheimer’s disease patients and APP transgenic mice are accompanied by impaired neurogenesis. *Journal of Neuroscience* **30**, 12252–12262 (2010).
35. Pulkkinen, H. H. *et al.* BMP6/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF. *Angiogenesis* **24**, 129–144 (2021).
36. Hu, M.-M. & Shu, H.-B. Multifaceted roles of TRIM38 in innate immune and inflammatory responses. *Cell Mol Immunol* **14**, 331–338 (2017).
37. Hu, S., Li, Y., Wang, B. & Peng, K. TRIM38 protects chondrocytes from IL-1 β -induced apoptosis and degeneration via negatively modulating nuclear factor (NF)- κ B signaling. *Int Immunopharmacol* **99**, (2021).
38. Koike, Y. *et al.* Genetic insights into ossification of the posterior longitudinal ligament of the spine. *Elife* **12**, (2023).
39. Nakajima, M. *et al.* A genome-wide association study identifies susceptibility loci for ossification of the posterior longitudinal ligament of the spine. *Nat Genet* **46**, 1012–1016 (2014).

40. Jokoji, G. *et al.* CDC5L promotes early chondrocyte differentiation and proliferation by modulating pre-mRNA splicing of SOX9, COL2A1, and WEE1. *Journal of Biological Chemistry* **297**, 100994 (2021).
41. Kim, S. K. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PLoS One* **13**, e0200785 (2018).
42. Kemp, J. P., Medina-Gomez, C., Tobias, J. H., Rivadeneira, F. & Evans, D. M. The case for genome-wide association studies of bone acquisition in paediatric and adolescent populations. *Bonekey Rep* **5**, 796 (2016).
43. Estrada, K. *et al.* Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* **44**, 491–501 (2012).
44. Bian, Q. *et al.* Excessive Activation of TGF β by Spinal Instability Causes Vertebral Endplate Sclerosis. *Sci Rep* **6**, 27093 (2016).
45. Hegewald, A. A. *et al.* Effects of initial boost with TGF-beta 1 and grade of intervertebral disc degeneration on 3D culture of human annulus fibrosus cells. *J Orthop Surg Res* **9**, 73 (2014).
46. Pham, D., Vincentz, J. W., Firulli, A. B. & Kaplan, M. H. Twist1 Regulates *Ifng* Expression in Th1 Cells by Interfering with Runx3 Function. *The Journal of Immunology* **189**, 832–840 (2012).
47. Salo, V. *et al.* Genome-wide meta-analysis conducted in three large biobanks expands the genetic landscape of lumbar disc herniations. doi:10.1101/2023.10.15.23296916.
48. Bjornsdottir, G. *et al.* Rare SLC13A1 variants associate with intervertebral disc disorder highlighting role of sulfate in disc pathology. *Nat Commun* **13**, 634 (2022).
49. Soranzo, N. *et al.* Meta-Analysis of Genome-Wide Scans for Human Adult Stature Identifies Novel Loci and Associations with Measures of Skeletal Frame Size. *PLoS Genet* **5**, e1000445 (2009).
50. Johansson, Å. *et al.* Common variants in the JAZF1 gene associated with height identified by linkage and genome-wide association analysis. *Hum Mol Genet* **18**, 373–380 (2009).
51. Nakamichi, R. & Asahara, H. The transcription factors regulating intervertebral disc development. *JOR Spine* **3**, (2020).
52. Nakamichi, R. *et al.* Mohawk promotes the maintenance and regeneration of the outer annulus fibrosus of intervertebral discs. *Nat Commun* **7**, 12503 (2016).
53. Shen, L. *et al.* miR-448 downregulates MPPED2 to promote cancer proliferation and inhibit apoptosis in oral squamous cell carcinoma. *Exp Ther Med* **12**, 2747–2752 (2016).
54. Schimunek, L. *et al.* MPPED2 Polymorphism Is Associated With Altered Systemic Inflammation and Adverse Trauma Outcomes. *Front Genet* **10**, (2019).
55. Liu, C. F. & Lefebvre, V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res* **43**, 8183–8203 (2015).
56. Lefebvre, V., Li, P. & de Crombrughe, B. A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. *EMBO J* **17**, 5718–33 (1998).
57. Han, Y. & Lefebvre, V. L-Sox5 and Sox6 Drive Expression of the Aggrecan Gene in Cartilage by Securing Binding of Sox9 to a Far-Upstream Enhancer. *Mol Cell Biol* **28**, 4999–5013 (2008).
58. Nakajima, M., Koido, M., Guo, L., Terao, C. & Ikegawa, S. A novel CCDC91 isoform associated with ossification of the posterior longitudinal ligament of the spine works as

- a non-coding RNA to regulate osteogenic genes. *The American Journal of Human Genetics* **110**, 638–647 (2023).
59. Tan, Z. *et al.* Synergistic co-regulation and competition by a SOX9-GLI-FOXA phasic transcriptional network coordinate chondrocyte differentiation transitions. *PLoS Genet* **14**, e1007346 (2018).
 60. Inui, M. *et al.* USP15 is a deubiquitylating enzyme for receptor-activated SMADs. *Nat Cell Biol* **13**, 1368–1375 (2011).
 61. Meola, N. *et al.* Identification of a Nuclear Exosome Decay Pathway for Processed Transcripts. *Mol Cell* **64**, 520–533 (2016).
 62. Najmabadi, H. *et al.* Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* **478**, 57–63 (2011).
 63. Revy, P., Kannengiesser, C. & Bertuch, A. A. Genetics of human telomere biology disorders. *Nat Rev Genet* **24**, 86–108 (2023).
 64. Itoh, Y. *et al.* A common SNP risk variant MT1-MMP causative for Dupuytren's disease has a specific defect in collagenolytic activity. *Matrix Biology* **97**, 20–39 (2021).
 65. Kosaka, H. *et al.* Pathomechanism of Loss of Elasticity and Hypertrophy of Lumbar Ligamentum Flavum in Elderly Patients With Lumbar Spinal Canal Stenosis. *Spine (Phila Pa 1976)* **32**, 2805–2811 (2007).
 66. Osthues, T. *et al.* The Lipid Receptor G2A (GPR132) Mediates Macrophage Migration in Nerve Injury-Induced Neuropathic Pain. *Cells* **9**, (2020).
 67. Stykarsdottir, U. *et al.* Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31. *Nat Genet* **46**, 498–502 (2014).
 68. Chu, M. *et al.* The rs4238326 polymorphism in ALDH1A2 gene potentially associated with non-post traumatic knee osteoarthritis susceptibility: a two-stage population-based study. *Osteoarthritis Cartilage* **25**, 1062–1067 (2017).
 69. Zhu, L. *et al.* Variants in *ALDH1A2* reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis. *Sci Transl Med* **14**, (2022).
 70. Smith, T., Ferreira, L. R., Hebert, C., Norris, K. & Sauk, J. J. Hsp47 and cyclophilin B traverse the endoplasmic reticulum with procollagen into pre-Golgi intermediate vesicles. A role for Hsp47 and cyclophilin B in the export of procollagen from the endoplasmic reticulum. *J Biol Chem* **270**, 18323–8 (1995).
 71. van Dijk, F. S. *et al.* PPIB Mutations Cause Severe Osteogenesis Imperfecta. *The American Journal of Human Genetics* **85**, 521–527 (2009).
 72. Epstein, P. M., Basole, C. & Brocke, S. The Role of PDE8 in T Cell Recruitment and Function in Inflammation. *Front Cell Dev Biol* **9**, (2021).
 73. Wang, H. *et al.* Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. *Biochemistry* **47**, 12760–8 (2008).
 74. Allen, E. *et al.* Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. *Nature* **438**, 224–228 (2005).
 75. Martens, N. *et al.* Suppressor of Cytokine Signaling 7 Inhibits Prolactin, Growth Hormone, and Leptin Signaling by Interacting with STAT5 or STAT3 and Attenuating Their Nuclear Translocation. *Journal of Biological Chemistry* **280**, 13817–13823 (2005).
 76. Jho, E. *et al.* Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. *Mol Cell Biol* **22**, 1172–83 (2002).
 77. Houshyar, K. S. *et al.* Wnt Pathway in Bone Repair and Regeneration - What Do We Know So Far. *Front Cell Dev Biol* **6**, 170 (2018).

78. Li, X. *et al.* The adaptor protein Nck-1 couples the netrin-1 receptor DCC (deleted in colorectal cancer) to the activation of the small GTPase Rac1 through an atypical mechanism. *Journal of Biological Chemistry* **277**, 37788–37797 (2002).
79. Bu, G. *et al.* Increased expression of netrin-1 and its deleted in colorectal cancer receptor in human diseased lumbar intervertebral disc compared with autopsy control. *Spine (Phila Pa 1976)* **37**, 2074–2081 (2012).
80. Cousminer, D. L. *et al.* Genome-wide association study implicates novel loci and reveals candidate effector genes for longitudinal pediatric bone accrual. *Genome Biol* **22**, 1 (2021).
81. Zheng, Z. *et al.* CRLF1 Is a Key Regulator in the Ligamentum Flavum Hypertrophy. *Front Cell Dev Biol* **8**, (2020).
82. Xi, P., Ding, D., Zhou, J., Wang, M. & Cong, Y.-S. DDRGK1 regulates NF- κ B activity by modulating I κ B α stability. *PLoS One* **8**, e64231 (2013).
83. Egunsola, A. T. *et al.* Loss of DDRGK1 modulates SOX9 ubiquitination in spondyloepimetaphyseal dysplasia. *J Clin Invest* **127**, 1475–1484 (2017).
84. Raouf, A. & Seth, A. Ets transcription factors and targets in osteogenesis. *Oncogene* **19**, 6455–6463 (2000).
85. Malik, N. *et al.* Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. *Mol Cell Biol* **9**, 2847–53 (1989).
86. Sims, N. A. & Quinn, J. M. W. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. *Bonekey Rep* **3**, (2014).
87. Liu, T. *et al.* Chordin-Like 1 Improves Osteogenesis of Bone Marrow Mesenchymal Stem Cells Through Enhancing BMP4-SMAD Pathway. *Front Endocrinol (Lausanne)* **10**, (2019).
88. Gao, W.-L., Zhang, S.-Q., Zhang, H., Wan, B. & Yin, Z.-S. Chordin-like protein 1 promotes neuronal differentiation by inhibiting bone morphogenetic protein-4 in neural stem cells. *Mol Med Rep* **7**, 1143–8 (2013).
89. Kurakazu, I. *et al.* FOXO1 transcription factor regulates chondrogenic differentiation through transforming growth factor β 1 signaling. *Journal of Biological Chemistry* **294**, 17555–17569 (2019).
90. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**, 76–82 (2011).
91. Bakshi, A. *et al.* Fast set-based association analysis using summary data from GWAS identifies novel gene loci for human complex traits. *Sci Rep* **6**, (2016).
92. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* **10**, e1004383 (2014).
93. Martin, F. J. *et al.* Ensembl 2023. *Nucleic Acids Res* **51**, D933–D941 (2023).
94. Sliz, E. *et al.* Evidence of a causal effect of genetic tendency to gain muscle mass on uterine leiomyomata. *Nat Commun* **14**, 542 (2023).
95. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).